Tumors or cancer of the human BREAST.
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
Pathological processes of the BREAST.
The nursing of an infant at the breast.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Radiographic examination of the breast.
Neoplasms containing cyst-like formations or producing mucin or serum.
A cell line derived from cultured tumor cells.
A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Implants used to reconstruct and/or cosmetically enhance the female breast. They have an outer shell or envelope of silicone elastomer and are filled with either saline or silicone gel. The outer shell may be either smooth or textured.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
The inspection of one's breasts, usually for signs of disease, especially neoplastic disease.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tumors or cancer of the SKIN.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
DNA present in neoplastic tissue.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Surgical procedure to remove one or both breasts.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the LUNG.
Tumors or cancers of the KIDNEY.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Tumors or cancer located in bone tissue or specific BONES.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.
Tumors or cancer of the THYROID GLAND.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Tumors or cancer of the LIVER.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.
An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)
Tumors or cancer of the PAROTID GLAND.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Surgical reconstruction of the breast including both augmentation and reduction.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.
Tumors or cancer of the APPENDIX.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
The conic organs which usually give outlet to milk from the mammary glands.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Tumors or cancer of the ENDOCRINE GLANDS.
An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.)
Glandular tissue in the BREAST of human that is under the influence of hormones such as ESTROGENS; PROGESTINS; and PROLACTIN. In WOMEN, after PARTURITION, the mammary glands secrete milk (MILK, HUMAN) for the nourishment of the young.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.
Elements of limited time intervals, contributing to particular results or situations.
A malignant epithelial tumor with a glandular organization.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the SALIVARY GLANDS.
Tumors or cancer of the EYE.
Tumors or cancer of the UTERUS.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Area of the human body underneath the SHOULDER JOINT, also known as the armpit or underarm.
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
Surgical insertion of an inert sac filled with silicone or other material to augment the female form cosmetically.
Tumors or cancer of the NOSE.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)
Tumors or cancer of the COLON.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)
RNA present in neoplastic tissue.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
A benign epithelial tumor with a glandular organization.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A general term for various neoplastic diseases of the lymphoid tissue.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Tumors or cancer of the INTESTINES.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
The erbB-2 gene is a proto-oncogene that codes for the erbB-2 receptor (RECEPTOR, ERBB-2), a protein with structural features similar to the epidermal growth factor receptor. Its name originates from the viral oncogene homolog (v-erbB) which is a truncated form of the chicken erbB gene found in the avian erythroblastosis virus. Overexpression and amplification of the gene is associated with a significant number of adenocarcinomas. The human c-erbB-2 gene is located at 17q21.2.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Neoplasms composed of more than one type of neoplastic tissue.
Organized periodic procedures performed on large groups of people for the purpose of detecting disease.
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tumors or cancer of the MANDIBLE.
A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed)
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Tumors or cancer of the BILE DUCTS.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Cancer or tumors of the MAXILLA or upper jaw.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
Tumors or cancer of the anal gland.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Antibodies produced by a single clone of cells.
Tumors or cancer of the STOMACH.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Tumors or cancer of the DUODENUM.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Total mastectomy with axillary node dissection, but with preservation of the pectoral muscles.
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
Tumors or cancer of the MOUTH.
Using fine needles (finer than 22-gauge) to remove tissue or fluid specimens from the living body for examination in the pathology laboratory and for disease diagnosis.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
Tumors or cancers of the ADRENAL CORTEX.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
Tumors or cancer of the MEDIASTINUM.
Tumors or cancer of the URINARY BLADDER.
Transplantation between animals of different species.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
Neoplasms composed of cells from the deepest layer of the epidermis. The concept does not refer to neoplasms located in the stratum basale.

Diphtheria toxin effects on human cells in tissue culture. (1/42895)

HeLa cells exposed to a single sublethal concentration of diphtheria toxin were found to have diminished sensitivity when subsequently reexposed to the toxin. Three cells strains exhibiting toxin resistance were developed. In the cells that had previously been exposed to toxin at 0.015 mug/ml, 50% inhibition of protein synthesis required a toxin concentration of 0.3 mug/ml, which is more than 10 times that required in normal HeLa cells. There appears to be a threshold level of diphtheria toxin action. Concentrations of toxin greater than that required for 50% inhibition of protein synthesis (0.01 mug/ml) are associated with cytotoxicity, whereas those below this concentration may not be lethal. Several established human cell lines of both normal and neoplastic origin were tested for their sensitivity to the effects of the toxin. No special sensitivity was observed with the cells of tumor origin. Fifty % inhibition of protein synthesis of HeLa cells was achieved with diphtheria toxin (0.01 mug/ml) as compared to the normal human cell lines tested (0.03 and 0.5 mug/ml) and a cell line derived from a human pancreatic adenocarcinoma (0.2 mug/ml). A human breast carcinoma cell line showed a maximum of 45% inhibition of protein synthesis. This required a diphtheria toxin concentration of 5 mug/ml. These results suggest that different human cell lines show wide variation in their sensitivity to the toxin.  (+info)

The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. (2/42895)

We have established or characterized six lines of human breast cancer maintained in long-term tissue culture for at least 1 year and have examined these lines for estrogen responsiveness. One of these cell lines, MCF-7, shows marked stimulation of macromolecular synthesis and cell division with physiological concentrations of estradiol. Antiestrogens are strongly inhibitory, and at concentrations greater than 3 X 10(-7) M they kill cells. Antiestrogen effects are prevented by simultaneous treatment with estradiol or reversed by addition of estradiol to cells incubated in antiestrogen. Responsive cell lines contain high-affinity specific estradiol receptors. Antiestrogens compete with estradiol for these receptors but have a lower apparent affinity for the receptor than estrogens. Stimulation of cells by estrogens is biphasic, with inhibition and cell death at concentrations of 17beta-estradiol or diethylstilbestrol exceeding 10(-7) M. Killing by high concentrations of estrogen is probably a nonspecific effect in that we observe this response with 17alpha-estradiol at equivalent concentrations and in the otherwise unresponsive cells that contain no estrogen receptor sites.  (+info)

The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture. (3/42895)

Glucocorticoids, at physiological concentration, inhibit cell division and thymidine incorporation in three lines of human breast cancer maintained in long-term tissue culture. At steroid concentrations sufficient to inhibit thymidine incorporation 50%, little or no effect is seen on protein synthesis 48 hr after hormone addition. All three of these lines are shown to have glucocorticoid receptors demonstrable by competitive protein binding assays. Receptors are extensively characterized in one line by sucrose density gradient analysis and binding specificity studies. Good correlation between receptor-binding specificity and biological activity is found except for progesterone, which binds to glucocorticoid receptor but is noninhibitory. Cross-competition and quantification studies demonstrate a separate receptor for progesterone. This receptor has limited binding specificities restricted largely to progestational agents, whereas the glucocorticoid receptor bound both glucocorticoids and progesterone. Two other human breast cancer lines neither contain glucocorticoid receptor nor are inhibited by glucocorticoids. It is concluded that in some cases glucocorticoids can directly limit growth in human breast cancer in vitro without requiring alterations in other trophic hormones.  (+info)

The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. (4/42895)

We have examined five human breast cancer cell lines in continuous tissue culture for androgen responsiveness. One of these cell lines shows a 2- to 4-fold stimulation of thymidine incorporation into DNA, apparent as early as 10 hr following androgen addition to cells incubated in serum-free medium. This stimulation is accompanied by an acceleration in cell replication. Antiandrogens [cyproterone acetate (6-chloro-17alpha-acetate-1,2alpha-methylene-4,6-pregnadiene-3,20-dione) and R2956 (17beta-hydroxy-2,2,17alpha-trimethoxyestra-4,9,11-triene-1-one)] inhibit both protein and DNA synthesis below control levels and block androgen-mediated stimulation. Prolonged incubation (greater than 72 hr) in antiandrogen is lethal. The MCF- cell line contains high-affinity receptors for androgenic steroids demonstrable by sucrose density gradients and competitive protein binding analysis. By cross-competition studies, androgen receptors are distinguishable from estrogen receptors also found in this cell line. Concentrations of steroid that saturate androgen receptor sites in vitro are about 1000 times lower than concentrations that maximally stimulate the cells. Changes in quantity and affinity of androgen binding to intact cells at 37 degrees as compared with usual binding techniques using cytosol preparation at 0 degrees do not explain this difference between dissociation of binding and effect. However, this difference can be explained by conversion of [3H]-5alpha-dihydrotestosterone to 5alpha-androstanediol and more polar metabolites at 37 degrees. An examination of incubation media, cytoplasmic extracts and crude nuclear pellets reveals probable conversion of [3H]testosterone to [3H]-5alpha-dihydrotestosterone. Our data provide compelling evidence that some human breast cancer, at least in vitro, may be androgen dependent.  (+info)

Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. (5/42895)

Elevated levels of Src kinase activity have been reported in a number of human cancers, including colon and breast cancer. We have analysed four human breast tumor cell lines that exhibit high levels of Src kinase activity, and have determined that these cell lines also exhibit a high level of a phosphotyrosine phosphatase activity that recognizes the Src carboxy-terminal P-Tyr530 negative regulatory site. Total Src kinase activity in these cell lines is elevated as much as 30-fold over activity in normal control cells and specific activity is elevated as much as 5.6-fold. When the breast tumor cells were grown in the presence of the tyrosine phosphatase inhibitor vanadate, Src kinase activity was reduced in all four breast tumor cell lines, suggesting that Src was being activated by a phosphatase which could recognize the Tyr530 negative regulatory site. In fractionated cell extracts from the breast tumor cells, we found elevated levels of a membrane associated tyrosine phosphatase activity that preferentially dephosphorylated a Src family carboxy-terminal phosphopeptide containing the regulatory tyrosine 530 site. Src was hypophosphorylated in vivo at tyrosine 530 in at least two of the tumor cell lines, further suggesting that Src was being activated by a phosphatase in these cells. In preliminary immunoprecipitation and antibody depletion experiments, we were unable to correlate the major portion of this phosphatase activity with several known phosphatases.  (+info)

Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. (6/42895)

Increased breast cancer growth has been associated with increased expression of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases (RTKs). Upon activation, RTKs may transmit their oncogenic signals by binding to the growth factor receptor bound protein-2 (Grb2), which in turn binds to SOS and activates the Ras/Raf/MEK/mitogen-activated protein (MAP) kinase pathway. Grb2 is important for the transformation of fibroblasts by EGFR and ErbB2; however, whether Grb2 is also important for the proliferation of breast cancer cells expressing these RTKs is unclear. We have used liposomes to deliver nuclease-resistant antisense oligodeoxynucleotides (oligos) specific for the GRB2 mRNA to breast cancer cells. Grb2 protein downregulation could inhibit breast cancer cell growth; the degree of growth inhibition was dependent upon the activation and/or endogenous levels of the RTKs. Grb2 inhibition led to MAP kinase inactivation in EGFR, but not in ErbB2, breast cancer cells, suggesting that different pathways might be used by EGFR and ErbB2 to regulate breast cancer growth.  (+info)

Increased expression of fibroblast growth factor 8 in human breast cancer. (7/42895)

Fibroblast growth factor 8 (FGF8) is an important developmental protein which is oncogenic and able to cooperate with wnt-1 to produce mouse mammary carcinoma. The level of expression of FGF8 mRNA was measured in 68 breast cancers and 24 non-malignant breast tissues. Elevated levels of FGF8 mRNA were found in malignant compared to non-malignant breast tissues with significantly more malignant tissues expressing FGF8 (P=0.019) at significantly higher levels (P=0.031). In situ hybridization of breast cancer tissues and analysis of purified populations of normal epithelial cells and breast cancer cell lines showed that malignant epithelial cells expressed FGF8 mRNA at high levels compared to non-malignant epithelial and myoepithelial cells and fibroblasts. Although two of the receptors which FGF8 binds to (FGFR2-IIIc, FGFR3-IIIc) are not expressed in breast cancer cells, an autocrine activation loop is possible since expression of fibroblast growth factor receptor (FGFR) 4 and FGFR1 are retained in malignant epithelial cells. This is the first member of the FGF family to have increased expression in breast cancer and a potential autocrine role in its progression.  (+info)

Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells. (8/42895)

Loss of p53 function by mutational inactivation is the most common marker of the cancerous phenotype. Previous studies from our laboratory have demonstrated 17 beta estradiol (E2) induction of p53 protein expression in breast cancer cells. Although direct effects of E2 on the expression of p53 gene are not known, the steroid is a potent regulator of c-Myc transcription. In the present studies, we have examined the ability of E2 and antiestrogens to regulate the P1 promoter of the p53 gene which contains a c-Myc responsive element. Estrogen receptor (ER)-positive T47D and MCF-7 cells were transiently transfected with the P1CAT reporter plasmid and levels of CAT activity in response to serum, E2 and antiestrogens were monitored. Factors in serum were noted to be the dominant inducers of chloramphenicol acetyltransferase (CAT) expression in MCF-7 cells. The levels of CAT were drastically reduced when cells were maintained in serum free medium (SFM). However, a subtle ER-mediated induction of CAT expression was detectable when MCF-7 cells, cultured in SFM, were treated with E2. In serum-stimulated T47D cells, the CAT expression was minimal. The full ER antagonist, ICI 182 780 (ICI) had no effect. Treatment with E2 or 4-hydroxy tamoxifen (OHT) resulted in P1CAT induction; OHT was more effective than E2. Consistent with c-Myc regulation of the P1 promoter, E2 stimulated endogenous c-Myc in both cell lines. Two forms of c-Myc were expressed independent of E2 stimuli. The expression of a third more rapidly migrating form was E2-dependent and ER-mediated since it was blocked by the full ER antagonist, ICI, but not by the ER agonist/antagonist OHT. These data demonstrate both ER-mediated and ER-independent regulation of c-Myc and the P1 promoter of the p53 gene, and show differential effects of the two classes of antiestrogens in their ability to induce the P1 promoter of the p53 gene in breast cancer cells.  (+info)

RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving combination chemotherapy together with or without bevacizumab is more effective in treating patients with nonmetastatic breast cancer.. PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy works compared with giving combination chemotherapy together with bevacizumab in treating patients with nonmetastatic breast cancer. ...
TY - JOUR. T1 - Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer. T2 - Results of International Breast Cancer Study Group trial 15-95. AU - Basser, Russell L.. AU - ONeil, Anne. AU - Martinelli, Giovanni. AU - Green, Michael D.. AU - Peccatori, Fedro. AU - Cinieri, Severio. AU - Caotes, Alan S.. AU - Gelber, Richard D.. AU - Aebi, Stefan. AU - Castiglione-Gertsch, Monica. AU - Viale, Guiseppe. AU - Price, Karen N.. AU - Goldhirsch, Aron. PY - 2006/1/20. Y1 - 2006/1/20. N2 - Purpose: To compare adjuvant dose-intensive epirubicin and cyclophosphamide chemotherapy administered with filgrastim and progenitor cell support (DI-EC) with standard-dose anthracycline-based chemotherapy (SD-CT) for patients with early-stage breast cancer and a high risk of relapse, defined as stage II disease with 10 or more positive axillary nodes; or an estrogen receptor-negative or stage III tumor with five or more positive axillary nodes. Patients and Methods: Three hundred ...
Background: Young breast cancer occupies a higher and higher proportion of breast cancer, especially in Asia, and is associated with a more unfavorable prognosis compared with the disease arising in older women. However, the poor prognosis of young breast cancer cannot be fully explained by the clinical and molecular factors. Methods: This study investigated 1125 Chinese breast cancer patients diagnosed from 2009 to 2013. A data mining of gene expression profiles was performed for the young and older breast cancer patients, identifying significantly differentially expressed genes. Quantitative RT-PCR, Western blotting and immunohistochemistry assay were carried out for the clinical sample validations. Results: The investigation firstly displayed that young patients (≤45 years) accounted for 47.6 % (535/1125) of breast cancer, and clinically associated with some unfavorable factors related to poor prognosis, such as invasive pathological type, high tumor grade, lymph node positive, ER ...
Clinical trial for Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Stage II Breast Cancer | Triple Negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | Stage IA Breast Cancer , MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
How long do people usually live with untreated breast cancer - How long do people usually live with untreated breast cancer? Variable. This is highly dependent on the cancer type and stage of presentation. Some aggressive forms of cancer may take over vital organs within months; other breast cancers may rarely spread to other organs and may be indolent for years and years. What remains true is that there is no benefit of watchful waiting when it comes to breast cancer: all else being equal, early diagnosis can save lives.
Title:Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66. VOLUME: 13 ISSUE: 3. Author(s):Leila Farahmand, Sepideh Mansouri, Narges Jafarbeik-Iravani, Azin Teymourzadeh and Keivan Majidzadeh-A*. Affiliation:Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran. Keywords:Alternative growth cascades, breast cancer, receptor tyrosine kinases, signaling pathways, stemness phenotype, tamoxifen resistance.. Abstract:Background: Tamoxifen is widely administered ...
Despite progress in the management of breast cancer, the molecular underpinnings of clinically aggressive subtypes of the disease are not well-understood. Here, we show that activation of Notch developmental signaling in estrogen receptor (ER)-negative breast cancer cells results in direct transcriptional up-regulation of the apoptosis inhibitor and cell cycle regulator survivin. This response is associated with increased expression of survivin at mitosis, enhanced cell proliferation, and heightened viability at cell division. Conversely, targeting Notch signaling with a peptidyl gamma-secretase inhibitor suppressed survivin levels, induced apoptosis, abolished colony formation in soft agar, and inhibited localized and metastatic tumor growth in mice, without organ or systemic toxicity. In contrast, ER+ breast cancer cells, or various normal cell types, were insensitive to Notch stimulation. Therefore, ER- breast cancer cells become dependent on Notch-survivin signaling for their maintenance, in vivo.
TY - JOUR. T1 - Competing Risk of Death in Elderly Patients with Newly Diagnosed Stage I Breast Cancer. AU - Wasif, Nabil. AU - Neville, Matthew. AU - Gray, Richard. AU - Cronin, Patricia. AU - Pockaj, Barbara A. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Background: The majority of newly diagnosed breast cancers in the US are in women aged older than 65 years who can have additional comorbidities. Balancing the risks and benefits of treatment should take into account these competing risks of death. Study Design: The Surveillance, Epidemiology, and End Results Program-Medicare database was used to identify women with stage I breast cancer undergoing operations from 2004-2012. Using neural network analysis, comorbidities associated with mortality were grouped into clinically relevant categories. Cumulative incidence graphs and Fine and Gray competing risk regression analyses were used to study the association of age, race, comorbidity groupings, and tumor variables with 3 competing mortality outcomes: ...
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.s profile, publications, research topics, and co-authors
The Ets-1 transcription factor is a candidate breast cancer oncogene that regulates the expression of genes involved in tumor progression and metastasis. Ets-1 signaling has also been linked to the development of a basal-like breast cancer phenotype. We recently described a nitric oxide (NO)-induced gene signature that is associated with poor disease outcome in estrogen receptor-negative (ER-) breast cancer and contains both stem cell-like and basal-like components. Thus, we examined the role of Ets-1 in NO signaling and NO-induced phenotypes in ER- human breast cancer cells. Promoter region analyses were performed on genes upregulated in inducible nitric oxide synthase (NOS2) high expressing tumors for Ets-binding sites. In vitro mechanisms were examined in human basal-like breast cancer cells lines. NO signaling effects were studied using either forced NOS2 expression or the use of a chemical NO-donor, diethlylenetriamine NONOate (DETANO). Promoter region analysis of genes that are up-regulated in
Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy (surgery and radiotherapy) and systemic treatment (chemo-, endocrine, and targeted therapies). Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes. Historically, breast cancer was treated with radical surgery alone. Advances in the understanding of the natural course of breast cancer as well as the development of systemic therapies allowed for the use of breast-conserving surgeries, however, the nomenclature of viewing non-surgical management from the viewpoint of the definitive surgery lends to two adjectives connected with treatment timelines: adjuvant (after surgery) and neoadjuvant (before surgery). The mainstay ...
Breast cancer is considered as a fatal disease and it is known to be the number one cause of cancer fatality in women. According to American cancer society, an estimated 1.3 million new breast cancer instances are detected every year which includes 465,000 deaths. In order to productively tackle this devastating disease, we must push innovative scientists to research cancer at its most basic stage. In other words, breast cancer research work should be done at its molecular stage. Also, besides the governments, private organizations must offer flexible budget to scientists who will be doing breast cancer research work.. Proper financial support of breast cancer investigation projects; can not only lead to better prevention methods but it can also assist towards earlier detection techniques and new anticancer drugs and cure.. Not so long ago, scientists who are working towards breast cancer research project, have created and successfully tested a breast cancer vaccine which is possibly to cure ...
Purpose: Mammographic density is one of the strongest risk factors for breast cancer. However, very little is known about how other breast cancer risk factors may modify the association between breast density and breast cancer. We investigated if associations of breast density and breast cancer differ according to the level of other known breast cancer risk factors.. Methods: This study included 1,044 incident breast cancer cases diagnosed within the Nurses Health Study cohort and 1,794 matched controls. Percent breast density, absolute dense and non-dense areas were measured from digitized film images with computer-assisted methods. Information on breast cancer risk factors was obtained prospectively from biennial questionnaires completed before the date of the cancer diagnosis for cancer cases and their matched controls. We used multivariate logistic regression to describe the association between breast density measures and breast cancer risk. The risk estimates were presented as odds ratios ...
TY - JOUR. T1 - External Validity of a Trial Comprised of Elderly Patients With Hormone Receptor-Positive Breast Cancer. AU - van de Water, Willemien. AU - Kiderlen, Mandy. AU - Bastiaannet, Esther. AU - Siesling, Sabine. AU - Westendorp, Rudi G.J.. AU - van de Velde, Cornelis J.H.. AU - Nortier, Johan W.R.. AU - Seynaeve, Caroline. AU - de Craen, Anton J.M.. AU - Liefers, Gerrit-Jan. PY - 2014. Y1 - 2014. N2 - Background: Inclusion in trials is selective, and thus results may not be generalizable to the general population. The aim of this study was to investigate the external validity of randomized clinical trial outcomes for elderly breast cancer patients.Methods: We compared characteristics and outcomes of breast cancer patients (n = 1325) who participated in a randomized clinical trial (Tamoxifen Exemestane Adjuvant Multinational trial) with unselected breast cancer patients of corresponding age from the general population (n = 1056). Dutch patients aged 65 years or older at diagnosis of ...
NBCC believes that research is the best weapon we have to end breast cancer and recognizes that the financial resources available to complete this task are not infinite. Therefore, it is critical that breast cancer research be as effective as possible. NBCC is dedicated to increasing the effectiveness of breast cancer research by collaborating with investigators and involving knowledgeable breast cancer advocates in all aspects of research design and oversight. NBCC has also made strides towards improving the effectiveness of breast cancer research by bringing together leading thinkers from many fields to create innovative research strategies and pioneer new research models. As a result of these experiences, NBCC has determined that certain values facilitate progress toward ending breast cancer.. Breast cancer research takes place within many disciplines, including, among others, basic science, clinical research, epidemiology, social sciences, and health services research. Generally, research ...
Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated. The purpose of classification is to select the best treatment. The effectiveness of a specific treatment is demonstrated for a specific breast cancer (usually by randomized, controlled trials). That treatment may not be effective in a different breast cancer. Some breast cancers are aggressive and life-threatening, and must be treated with aggressive treatments that have major adverse effects. Other breast cancers are less aggressive and can be treated with less aggressive treatments, such as lumpectomy. Treatment algorithms rely on breast cancer classification to define specific subgroups that are each treated according to the best ...
Fertility and pregnancy issues are of key importance for young breast cancer patients. Despite several advances in the field, there are still multiple unmet needs and barriers in discussing and dealing with these concerns. To address the significant challenges related to fertility and pregnancy issues, the PREgnancy and FERtility (PREFER) study was developed as a national comprehensive program aiming to optimize care and improve knowledge around these topics. The PREFER study is a prospective cohort study conducted across several Italian institution affiliated with the Gruppo Italiano Mammella (GIM) group evaluating patterns of care and clinical outcomes of young breast cancer patients dealing with fertility and pregnancy issues. It is composed of two distinctive studies: PREFER-FERTILITY and PREFER-PREGNANCY. The PREFER-FERTILITY study is enrolling premenopausal patients aged 18-45 years, diagnosed with non-metastatic breast cancer, who are candidates to (neo)adjuvant chemotherapy and not previously
The Hormonal therapy resistant estrogen-receptor positive metastatic breast cancer cohort (HORSE-BC) study is a multicenter observational study evaluating the efficacy and safety of secondary endocrine therapy (ET) for postmenopausal cases of metastatic breast cancer (MBC) with poor response to primary ET. In this initial report we analyze the HORSE-BC baseline data to clarify the current status of treatment selection for MBC in Japan. Baseline data for the 50 patients enrolled in HORSE-BC were analyzed, including patient characteristics, types of secondary ET, and reasons for selecting secondary ET. Postoperative recurrence was detected in 84% of patients (42/50) and de novo stage IV breast cancer in 16% (8/50). Forty-one patients (41/50; 82%) received fulvestrant, 5 patients (10%) received selective estrogen receptor modulators (SERMs), 3 patients (6%) received ET plus a mammalian target of rapamycin (mTOR) inhibitor, and 1 patient received an aromatase inhibitor (AI) as the secondary ET. ...
Tongshu Capsule Down-Regulates the Expression of Estrogen Receptor α and Suppresses Human Breast Cancer Cell Proliferation. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
More than two million American women are breast cancer survivors. Approximately one-third of these women are premenopausal at diagnosis and face issues related to reproduction as they undergo cancer treatment. Ovarian function after breast cancer diagnosis has implications on breast cancer prognosis, choice of adjuvant therapy and reproductive issues such as desire for fertility or concerns about menopause. Therefore, tools to accurately predict ovarian function in breast cancer survivors could significantly impact physicians and patients in counseling, medical and surgical treatment choices, and consideration of fertility preservation options.. The goal of this proposal is to identify pre-chemotherapy hormonal, genetic and ovarian imaging markers that can predict ovarian failure and characterize the course of ovarian function after chemotherapy. The investigators plan to follow a group of young women from breast cancer diagnosis to five years after chemotherapy. The investigators will study the ...
Even luminal A tumors - normally considered the easiest breast cancer tumors for doctors to eradicate and for the patient to survive - can still cause death a decade after they are found through cancer marker lab testing.. These findings, appearing in the journal Cancer Epidemiology, Biomarkers and Prevention, were compiled over the course of 21 years of monitoring 1,000 breast cancer patients at Kaiser Permanente Southern California.. It is important to consider breast cancer molecular subtypes in determining the optimal treatment for women with breast cancer. Women with luminal A tumors - the least aggressive but most common cancerous breast tumor - could benefit from extended treatment, said Reina Haque, lead study author from the Kaiser Permanente Southern California Department of Research and Evaluation.. Nonetheless, breast cancer patients have a high likelihood of surviving luminal A tumors, compared to the four other types of breast cancer listed by the Kaiser researchers. The Centers ...
Kellie Martens, M.A., a doctoral student at the University of Colorado Denver, works with Dr. Kristin Kilbourn in the field of psycho-oncology. She is interested in learning what influences quality of life in young breast cancer survivors, with the intention of designing support groups or ways of screening that might make adjusting to a breast cancer diagnosis less difficult for young women. Please refer to the flyers (below) for more information. Its easy to participate, as women must only complete an on-line survey (IRB approved). ...
TY - JOUR. T1 - Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. AU - Munzone, Elisabetta. AU - Gray, Kathryn P.. AU - Fumagalli, Caterina. AU - Guerini-Rocco, Elena. AU - Láng, István. AU - Ruhstaller, Thomas. AU - Gianni, Lorenzo. AU - Kammler, Roswitha. AU - Viale, Giuseppe. AU - Di Leo, Angelo. AU - Coates, Alan S.. AU - Gelber, Richard D.. AU - Regan, Meredith M.. AU - Goldhirsch, Aron. AU - Barberis, Massimo. AU - Colleoni, Marco. PY - 2018/7/1. Y1 - 2018/7/1. N2 - Purpose: We investigated the occurrence and the prognostic and predictive relationship of a selected number of somatic mutations in triple-negative breast cancer (TNBC) patients having known clinical outcomes treated within the IBCSG Trial 22-00. Methods: A matched case-control sampling selected patients enrolled in the IBCSG Trial 22-00 who had TNBC tumors, based on local assessment. Cases had invasive breast cancer recurrence (at local, regional, or ...
BioAssay record AID 103718 submitted by ChEMBL: In vitro cytotoxicity against human breast carcinoma cell line MCF-7 at 8.1*10e-5M.
This textbook provides a comprehensive overview of the state of the art knowledge of breast cancer management for the modern breast surgeon. It covers all aspects of multidisciplinary care including primary breast and axillary surgery, reconstruction and oncoplastic techniques, external beam
Operable breast cancer patients may experience late recurrences because of reactivation of dormant tumor cells within the bone marrow (BM). Identification of patients who would benefit from extended therapy is therefore needed. BM samples obtained pre- and post-surgery were previously analysed for presence of disseminated tumor cells (DTC) by a multimarker mRNA quantitative reverse-transcription PCR assay. Updated survival analyses were performed on all patient data (n = 191) and in a subgroup of patients alive and recurrence-free after 5 years (n = 156). DTC data were compared to the mitotic activity index (MAI) of the primary tumors. Median follow-up time was 15.3 years. Among the 191 patients, 49 (25.65%) experienced systemic relapse, 24 (49%) within 5-18 years after surgery. MAI and pre- and post-operative DTC status had significant prognostic value based on Kaplan-Meier analyses and multiple Cox regression in the overall patient cohort. With exclusion of patients who relapsed or died within 5 years
We undertook this study to determine whether women with increased breast density had a greater likelihood of developing invasive breast cancer following lumpectomy for DCIS when compared to women with lower breast density, adjusting for age and radiation treatment. Our findings support the only previous report examining the association between breast density and DCIS recurrence, which suggested that the rate of second breast events following a diagnosis of DCIS may be increased in women with high breast density (33). In this previous study, breast density was measured as a continuous variable which was then categorized into four breast density groups. The number or events was comparable to the current study, with 91 ipsilateral events and 28 contralateral events. When compared with the lowest density group (,25% dense), the highest density group (≥75% dense) had an adjusted relative risk of 3.2 [95% confidence interval (95% CI), 1.2-8.5] for any invasive cancer. In comparison, although we ...
Additional breast cancers found with MRI are sometimes larger and potentially more aggressive than those found on mammography, and in some cases, may necessitate a change in treatment plan.
...Many breast cancer patients are treated with a drug called tamoxifen. ... Resistances to drugs are the main reason why therapies fail and disea...By treating breast cancer cells in vitro with regular doses of tamoxif...If microRNA 375 levels are low breast cancer cells increase the produ...,MicroRNA,controls,malignancy,and,resistance,of,breast,cancer,cells,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
TY - JOUR. T1 - Reclaiming life on ones own terms. T2 - A grounded theory study of the process of breast cancer survivorship. AU - Sherman, Deborah Witt. AU - Rosedale, Mary. AU - Haber, Judith. PY - 2012/5. Y1 - 2012/5. N2 - Purpose/Objectives: To develop a substantive theory of the process of breast cancer survivorship. Research Approach: Grounded theory. Setting: A LISTSERV announcement posted on the SHARE Web site and purposeful recruitment of women known to be diagnosed and treated for breast cancer. Participants: 15 women diagnosed with early-stage breast cancer. Methodologic Approach: Constant comparative analysis. Main Research Variables: Breast cancer survivorship. Findings: The core variable identified was Reclaiming Life on Ones Own Terms. The perceptions and experiences of the participants revealed overall that the diagnosis of breast cancer was a turning point in life and the stimulus for change. That was followed by the recognition of breast cancer as now being a part of life, ...
Dent et al 20 showed that patients with Triple negative breast cancer has less lymph node metastases but is more aggressively. It may be due to hematogenous spread or lack of targetable treatment. Chengshuai Si et al 21 study showed that tumor size and tumor subtype show statistical significance with LN involvement. Luminal B type showed significant higher probability of LN involvement, Triple positive and triple negative breast cancer accounts the most and least possibility of LN involvement.. Emi Yoshihara et alHYPERLINK https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589678/ l R3″22 study showed that the incidence of ALNM was significantly associated with the presence of LVI (P,0.001), larger tumour size (P , 0.001), higher histologic grade (P , 0.001) and no effect of age. Elsayed M Ali1 et al23study evaluated 258 patients with invasive breast carcinomas, ER and PR expression were demonstrated in 78.7% and 76.4%, respectively and over-expression of HER-2/neu was detected in 13.2% of ...
Health, ...A gene target for drug resistance a triple-drug cocktail for triple n...SIMPLE FINGERTIP TEST MAY IDENTIFY BREAST CANCER PATIENTS AT RISK FOR ...CTS most often associated with computer keyboard typing is caused by...For the study researchers gathered and analyzed information on 104 wo...,Simple,fingertip,test,may,identify,breast,cancer,patients,at,risk,for,carpal,tunnel,syndrome,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Tamoxifen reduces recurrence risk among women treated for estrogen receptor-positive breast cancer. Its effectiveness partly depends on metabolic activation via cytochrome P450 2D6 (CYP2D6). Some medications compromise CYP2D6 activity and may lower plasma concentrations of active tamoxifen metabolites. We studied the association between concurrent use of tamoxifen and CYP2D6-inhibiting medications and breast cancer recurrence among Danish women diagnosed with early-stage, estrogen receptor-positive breast cancer. Using the Danish Breast Cancer Cooperative Group Registry, we identified 366 cases with local or distant breast cancer recurrence and 366 matched breast cancer controls. We ascertained concurrent prescription of CYP2D6-inhibiting medications during tamoxifen treatment by linking to the national prescription database covering all Danish pharmacies. We computed the breast cancer recurrence odds ratio (OR) and 95% confidence interval for each medication. The pooled recurrence OR was null ...
These new funds bring Susan G. Komens total breast cancer research investment to more than $1 billion since its inception in 1982, and investment in research focused on metastatic breast cancer to $210 million. Next to the U.S. government, Susan G. Komen is the largest nonprofit funder of breast cancer research in the world, and much of that investment has been awarded to scientists and research institutions in San Diego. As a local office, Susan G. Komen San Diego has invested more than $19 million in global breast cancer research and local breast health services since our inception in 1995.. In order to save more lives, we must address the main cause of breast cancer deaths: metastatic breast cancer, said George Sledge, Susan G. Komens Chief Scientific Advisor, M.D., Professor of Medicine, and Chief of the Division of Oncology in the Department of Medicine at Stanford University.. Metastatic (stage iv) breast cancer is the most advanced stage of breast cancer, which does not yet have a ...
Ductal means that the cancer starts inside the milk ducts, carcinoma refers to any cancer that begins in the skin or other tissues including breast tissue that cover or line the internal organs, and in situ means in its original place. When you have had DCIS, you are at higher risk for the cancer coming back or for developing a new breast cancer than a person who has never had breast cancer before.. Most recurrences happen within the 5 to 10 years after initial diagnosis. Learn what additional steps you can take to lower your risk of a new breast cancer diagnosis or a recurrence in the Lower Your Risk section. If breast cancer does come back after earlier DCIS treatment, the recurrence is non-invasive DCIS again about half the time and invasive about half the time.. According to the American Cancer Society, about 60, cases of DCIS are diagnosed in the United States each year, accounting for about 1 out of every 5 new breast cancer cases. There are two main reasons this number is so large and ...
Ductal means that the cancer starts inside the milk ducts, carcinoma refers to any cancer that begins in the skin or other tissues including breast tissue that cover or line the internal organs, and in situ means in its original place.. When you have had DCIS, you are at higher risk for the cancer coming back or for developing a new breast cancer than a person who has never had breast cancer before. Most recurrences happen within the 5 to 10 years after initial diagnosis. Learn what additional steps you can take to lower your risk of a new breast cancer diagnosis or a recurrence in the Lower Your Risk section.. If breast cancer does come back after earlier DCIS treatment, the recurrence is non-invasive DCIS again about half the time and invasive about half the time. According to the American Cancer Society, about 60, cases of DCIS are diagnosed in the United States each year, accounting for about 1 out of every 5 new breast cancer cases.. There are two main reasons this number is so large and ...
Background The aim of this retrospective study was to determine whether progesteron receptor (PgR) status have an influence on the prognosis of estrogen receptor positive (ER+)/HER2-negative breast carcinoma (BC).. Methods We retrospectively reviewed the medical files of 1680 operable BC patients (pts) diagnosed between 1996 and 2011 and 456 of whom ER,PgR and HER2 status known were included in this study. Patients were categorized into 2 groups; as group A (ER + /PgR-/HER2-negative) and group B (ER + /PgR + /HER2-negative). Twenty one percent (97 pts) of the pts were in group A.. Results Median follow up was 33.5 (0-177) months. Median age was 54 (21-90) years. Sixty-one percent (278) of the pts had node-positive BC. Sixty percent (276) of the pts were postmenopausal. Eighty percent (365) of the pts received adjuvant chemotherapy (ACT). Adjuvant hormonotherapy (AHT) was recommended to nearly all patients (mostly tamoxifen). Pts in group A had significantly higher lymph node positive disease as ...
Triple-negative (TN) breast cancer is an aggressive subtype of breast cancer associated with a unique set of epidemiologic and genetic risk factors. We conducted a two-stage genome-wide association study of TN breast cancer (stage 1: 1529 TN cases, 3399 controls; stage 2: 2148 cases, 1309 controls) to identify loci that influence TN breast cancer risk. Variants in the 19p13.1 and PTHLH loci showed genome-wide significant associations (P , 5 × 10(-) (8)) in stage 1 and 2 combined. Results also suggested a substantial enrichment of significantly associated variants among the single nucleotide polymorphisms (SNPs) analyzed in stage 2. Variants from 25 of 74 known breast cancer susceptibility loci were also associated with risk of TN breast cancer (P , 0.05). Associations with TN breast cancer were confirmed for 10 loci (LGR6, MDM4, CASP8, 2q35, 2p24.1, TERT-rs10069690, ESR1, TOX3, 19p13.1, RALY), and we identified associations with TN breast cancer for 15 additional breast cancer loci (P , 0.05: ...
BACKGROUND: Adjuvant trastuzumab has been routinely used in HER2-positive operable breast cancer patients. Prognostic factors remain to be well characterized in these patients and might correlate with primary and/or acquired resistance to trastuzumab.. PATIENTS AND METHODS: The study subjects were 78 HER2-positive operable breast cancer patients treated with adjuvant chemotherapy followed by 1-year trastuzumab between 2005 and 2010 in our institute. All breast tumors showed a HercepTest score of 3+ or that of 2+ and positive fluorescence in situ hybridization. Expression levels of HER1, phosphorylated HER2 (pY1248), HER3, HER4, and p53 were assessed by immunohistochemistry. Prognostic factors were investigated with univariate and multivariate analyses using the Kaplan-Meier/log-rank test and Cox proportional hazards model, respectively.. RESULTS: The median age and follow-up period of the patients were 54 years and 39 months, respectively. The mean tumor size was 2.1 cm and the node-positive ...
Physical activity after breast cancer diagnosis has been linked with prolonged survival and improved quality of life, but most participants in a large breast cancer study did not meet national physical activity guidelines after they were diagnosed. Moreover, African-American women were less likely to meet the guidelines than were White women.. Published online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings indicate that efforts to promote physical activity in breast cancer patients may need to be significantly enhanced.. The study, Racial differences in physical activity among breast cancer survivors: implications for breast cancer care, was led by Ms. Brionna Hair, epidemiology doctoral student at the University of North Carolina Gillings School of Global Public Health.. The U.S. Department of Health and Human Services and the American Cancer Society recommend that adults engage weekly in at least 150 minutes of moderate-intensity physical activity or 75 ...
Introduction: Identification of gene expression-based breast cancer subtypes is considered a critical means of prognostication. Genetic mutations along with epigenetic alterations contribute to gene-expression changes occurring in breast cancer. So far, these epigenetic contributions to sporadic breast cancer subtypes have not been well characterized, and only a limited understanding exists of the epigenetic mechanisms affected in those particular breast cancer subtypes. The present study was undertaken to dissect the breast cancer methylome and to deliver specific epigenotypes associated with particular breast cancer subtypes. Methods: By using a microarray approach, we analyzed DNA methylation in regulatory regions of 806 cancer-related genes in 28 breast cancer paired samples. We subsequently performed substantial technical and biologic validation by pyrosequencing, investigating the top qualifying 19 CpG regions in independent cohorts encompassing 47 basal-like, 44 ERBB2+ overexpressing, 48 ...
Background: We aimed to estimate the effect of alcohol consumption on breast cancer risk and to test whether overweight and obesity modifies this association. Methods: We included in the analysis 45,233 women enrolled in the Swedish Womens Lifestyle and Health study between 1991 and 1992. Participants were followed for occurrence of breast cancer and death until December 2009. Poisson regression models were used, and analyses were done for overall breast cancer and for estrogen receptor positive or negative (ER+, ER-) and progesterone receptor positive and negative (PR+, PR-) tumors separately. Results: A total of 1,385 breast cancer cases were ascertained during the follow-up period. Overall, we found no statistically significant association between alcohol intake and breast cancer risk after adjustment for confounding, with an estimated relative risk (RR) of 1.01 (95 % CI: 0.98-1.04) for an increment in alcohol consumption of 5 g/day. A statistically significant elevated breast cancer risk ...
Treatment of MCF 7 human breast cancer cells with three high affinity hydroxylated antiestrogens (Kd for the estrogen receptor = 0.11-0.45 nM) resulted in biphasic inhibition of cell growth. Administration of 0.1-1.0 nM of each drug caused a concentration-dependent decrease in cell number to a maximum of 30-40% of control but no further change was observed as the drug concentration was increased to 1 microM. Between 1.0 and 10 microM, however, a further concentration-dependent decrease in cell proliferation was observed. Among these compounds relative potencies paralleled their affinities for estrogen receptor in the 0.1-10 nM range but at micromolar concentrations this relationship did not hold. It is concluded that antiestrogens inhibit cell proliferation by two distinct mechanisms one of which involves the estrogen receptor and the other a mechanism yet to be defined. The parallel changes in cell cycle kinetic parameters accompanying growth inhibition in both concentration ranges i.e. accumulation of
If you are a woman and have been using any type of hormones to ease menopause symptoms, you could be upping breast cancer risk. Recent research shows that the use of these hormones over a long period of time ignites a minor increase in breast cancer risk.. Tracking the health of nearly 60,000 nurses, the recent study found that 10 years or more of hormone use was enough to raise breast cancer risk, although it is recommended that the lowest dose possible be used for the shortest amount of time possible. The research is surprising to many as some women who were taking estrogen alone were thought to have a decreased chance of developing breast cancer. And it is already known that taking pills combining estrogen and progestin - the most common type of hormone therapy - can increase breast cancer risk.. ...
BACKGROUND: Adjuvant! Online is a free web-based tool which predicts 10-year breast cancer outcomes and the efficacy of adjuvant therapy in patients with breast cancer. As its prognostic performance has only been validated in high income Caucasian populations, we validated the model in a middle income Asian setting. OBJECTIVES: This study aimed to determine the survival rate of breast cancer among the women of Malaysia and characteristics of the survivors. METHODS: Within the University Malaya Hospital-Based Breast Cancer Registry, all 631 women who were surgically treated for invasive non-metastatic breast cancer between 1993 and 2000 were identified. The discriminative performance of Adjuvant! Online was tested using receiver operating characteristic (ROC) analysis. Calibration of the model was evaluated by comparing predicted 10-year overall survival with observed 10-year survival. FINDINGS: Adjuvant! Online was fairly capable in discriminating between good and poor survivors, as attested by ...
Breast cancer patients and survivors have an increased risk of developing melanoma, the deadliest form of skin cancer. Research has shown genetics may play a role for women carrying a specific breast cancer susceptibility gene; the presence of abnormalities in the gene doubles the risk of melanoma.. The Skin Cancer Foundation recommends the following skin cancer prevention tips for breast cancer patients and survivors:. Beware of photosensitivity. Photosensitivity is an increased sensitivity or abnormal response of the skin to sunlight or artificial ultraviolet (UV) light; it can be caused by certain medical conditions and treatments. People with photosensitivity are at increased risk of developing skin cancers, and should be especially careful to seek shade and stay out of direct sunlight; wear sun-protective clothing, including wide-brimmed hats and UV-blocking sunglasses; and apply a broad-spectrum (UVA/UVB protection) sunscreen with SPF 30 or higher.. Be screened. People at high risk of ...
The authors retrospectively examined the contralateral prophylactic mastectomy (CPM) rate among 100 women with ductal carcinoma in situ who are BRCA negative. Of 100 women with ductal carcinoma in situ, 31 elected contralateral prophylactic mastectomy (CPM). Factors associated with increased likelihood of undergoing contralateral prophylactic mastectomy (CPM) among this cohort were: family history of ovarian cancer, marital status, reconstruction, mastectomy of the affected breast, and tamoxifen use.. Keywords: contralateral prophylactic mastectomy, BRCA negative ...
Scientists at the British Columbia Cancer Agency and University of British Columbia have identified new breast cancer genes. This is a discovery that may change the way breast cancer is diagnosed, as well the way it is treated. - Identification of New Breast Cancer Genes - Breast Cancer at BellaOnline
TY - JOUR. T1 - Longitudinal MRI Evaluation of Intracranial Development and Vascular Characteristics of Breast Cancer Brain Metastases in a Mouse Model. AU - Zhou, Heling. AU - Chen, Min. AU - Zhao, Dawen. PY - 2013/4/29. Y1 - 2013/4/29. N2 - Longitudinal MRI was applied to monitor intracranial initiation and development of brain metastases and assess tumor vascular volume and permeability in a mouse model of breast cancer brain metastases. Using a 9.4T system, high resolution anatomic MRI and dynamic susceptibility contrast (DSC) perfusion MRI were acquired at different time points after an intracardiac injection of brain-tropic breast cancer MDA-MB231BR-EGFP cells. Three weeks post injection, multifocal brain metastases were first observed with hyperintensity on T2-weighted images, but isointensity on T1-weighted post contrast images, indicating that blood-tumor-barrier (BTB) at early stage of brain metastases was impermeable. Follow-up MRI revealed intracranial tumor growth and increased ...
Contralateral prophylactic mastectomy: current perspectives Katharine Yao,1 Mark Sisco,2 Isabelle Bedrosian3 1Division of Surgical Oncology, Department of Surgery, 2Division of Plastic Surgery, Department of Surgery, NorthShore University HealthSystem, Evanston, IL, 3Department of Surgery, MD Anderson Cancer Center, Houston, TX, USA Abstract: There has been an increasing trend in the use of contralateral prophylactic mastectomy (CPM) in the United States among women diagnosed with unilateral breast cancer, particularly young women. Approximately one-third of women ,40 years old are undergoing CPM in the US. Most studies have shown that the CPM trend is mainly patient-driven, which reflects a changing environment for newly diagnosed breast cancer patients. The most common reason that women choose CPM is based on misperceptions about CPM’s effect on survival and overestimation of their contralateral breast cancer (CBC) risk. No prospective studies have shown survival benefit to CPM, and
Background: Metastasis is important in survival and the quality of life of female breast cancer patients. This study was run in order to investigate metastasis and its related factors in female breast cancer patients in Kerman province from 2005 to 2015. The aim of this study was to investigate the factors associated with secondary metastasis in female breast cancer patients in the largest province of Iran (Kerman). Materials and Methods: In this case-control study, medical records of women diagnosed with breast cancer between the years of 2005 to 2015 were studied. Among them, 200 breast cancer patients with secondary metastasis were randomly selected as cases and 400 patients without metastasis were selected as the control group. Backward logistic regression, chi-square test, t-test and Mann-Whitney-U test were performed for comparing the two groups in SPSS 22. Results: Disease stage at diagnosis was significantly associated with secondary metastasis (p|0.001). Female patients with stage III breast
A recent study reporting the absolute 20-year survival benefit from contralateral prophylactic mastectomy was less than 1% for women with stage I and II breast cancer without BRCA mutations runs counter to common perceptions about the risk of contralateral breast cancer among these women and the benefits of contralateral prophylactic mastectomy.1 (Earlier studies about perceptions of contralateral breast cancer and contralateral prophylactic mastectomy are referenced in the current study.). The less than 1% survival benefit was found among all subgroups studied-by age, estrogen receptor status, and cancer stage-although contralateral prophylactic mastectomy was more beneficial among younger women, those with stage I disease, and those with estrogen receptor-negative breast cancer, according to the report, published in the Journal of the National Cancer Institute.1 The stated aim of the study was to provide projected long-term survival information by using a stimulated Markov model for ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replacing BR243 \ BR243a for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases_80cores, replacing BR802 \ BR802b for more molecular products just contact us
SAN DIEGO, Dec. 7, 2017 /PRNewswire/ - Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that preclinical data demonstrating the sensitivity of triple negative breast cancer (TNBC) cell lines to PCM-075, its highly selective Polo-like kinase 1 (PLK1) Inhibitor, will be featured as a Poster Presentation at the 40th San Antonio Breast Cancer Symposium (SABCS) on December 7th, from 5:00 - 7:00 PM CST, in San Antonio, Texas.. Trovagenes poster entitled, Sensitivity of Triple Negative Breast Cancer Cell Lines to PCM-075, a Highly Selective Polo-like Kinase 1 Inhibitor, presents the preclinical analysis of 40 cancer cell lines and demonstrates that triple negative breast cancer (TNBC) cell lines are 20-fold more sensitive to PCM-075 than estrogen receptor positive (ER+) breast cancer cells lines.. Polo-like Kinase 1 (PLK1) is known to be over-expressed in many hematologic and solid tumor cancers, including breast cancer. PLK1 inhibition by PCM-075 induces ...
Breast cancer is the most common form of cancer and the second leading cause of malignancy-associated death in women worldwide. Estrogens are the main sex hormones in women. They are essential for the development and function of normal breast mammary glands; however, prolonged exposure to estrogens increases the risk of breast cancer development and progression. Approximately two-thirds of all breast cancer patients are positive for estrogen receptor (ER), but only 50% of those cases can benefit from antiestrogen therapy.. In this thesis we investigated the effects of estrogen, diet modification, and anti-estrogen drugs on several immune modulators in normal human breast tissue. We used the microdialysis technique to sample the immune modulators in situ in normal human breast tissue, in malignant breast tissue, and in tumor tissue from both the immune competent mice with murine breast cancer and immune deficient mice bearing human breast tumors. Furthermore, we also used ex vivo culture of ...
TY - JOUR. T1 - Unusual roles of caspase-8 in triple-negative breast cancer cell line MDA-MB-231. AU - De Blasio, Anna. AU - Di Fiore, Riccardo. AU - Morreale, Marco. AU - Carlisi, Daniela. AU - Drago-Ferrante, Rosa. AU - Montalbano, Mauro. AU - Scerri, Christian. AU - Tesoriere, Giovanni. AU - Vento, Renza. PY - 2016/1/1. Y1 - 2016/1/1. N2 - Triple-negative breast cancer (TNBC) is a clinically aggressive form of breast cancer that is unresponsive to endocrine agents or trastuzumab. TNBC accounts for ∼10-20% of all breast cancer cases and represents the form with the poorest prognosis. Patients with TNBC are at higher risk of early recurrence, mainly in the lungs, brain and soft tissue, therefore, there is an urgent need for new therapies. The present study was carried out in MDA-MB-231 cells, where we assessed the role of caspase-8 (casp-8), a critical effector of death receptors, also involved in non-apoptotic functions. Analysis of casp-8 mRNA and protein levels indicated that they were ...
Pregnancy is safe for women with estrogen receptor positive breast cancerSome people have basic questions about how pregnancy happens. Some may have questions about avoiding a pregnancy
Breast cancer brain metastases (BCBM) develop in about 20-30% of breast cancer (BC) patients. BCBM are associated with dismal prognosis not at least due to lack of valuable molecular therapeutic targets. The aim of the study was to identify new molecular biomarkers and targets in BCBM by using complementary state-of-the-art techniques. We compared array expression profiles of three BCBM with 16 non-brain metastatic BC and 16 primary brain tumors (prBT) using a false discovery rate (FDR) p | 0.05 and fold change (FC) | 2. Biofunctional analysis was conducted on the differentially expressed probe sets. High-density arrays were employed to detect copy number variations (CNVs) and whole exome sequencing (WES) with paired-end reads of 150 bp was utilized to detect gene mutations in the three BCBM. The top 370 probe sets that were differentially expressed between BCBM and both BC and prBT were in the majority comparably overexpressed in BCBM and included, e.g. the coding genes BCL3, BNIP3, BNIP3P1, BRIP1,
TY - JOUR. T1 - Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab. T2 - A multicenter retrospective observational study (JBCRG-C03 study). AU - Takada, M.. AU - Ishiguro, H.. AU - Nagai, S.. AU - Ohtani, S.. AU - Kawabata, H.. AU - Yanagita, Y.. AU - Hozumi, Y.. AU - Shimizu, C.. AU - Takao, S.. AU - Sato, N.. AU - Kosaka, Y.. AU - Sagara, Y.. AU - Iwata, H.. AU - Ohno, S.. AU - Kuroi, K.. AU - Masuda, N.. AU - Yamashiro, H.. AU - Sugimoto, M.. AU - Kondo, M.. AU - Naito, Yasuhiro. AU - Sasano, H.. AU - Inamoto, T.. AU - Morita, S.. AU - Toi, M.. PY - 2014. Y1 - 2014. N2 - We investigated the disease-free survival (DFS) of HER2-positive primary breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, as well as predictive factors for DFS and pathologic response. Data from 829 female patients treated between 2001 and 2010 were collected from 38 institutions in Japan. Predictive factors were evaluated using ...
Circulating tumor cells (CTCs) are tumor cells shed from either primary tumors or its metastases that circulate in the peripheral blood of patients with metastatic cancers. The molecular characterization of the CTCs is critical to identifying the key drivers of cancer metastasis and devising therapeutic approaches. However, the molecular characterization of CTCs is difficult to achieve because their isolation is a major technological challenge. CTCs from two triple negative breast cancer patients were enriched using CellSearch and single cells selected by DEPArray™. A TP53 R110 fs*13 mutation identified by next generation sequencing in the breast and chest skin biopsies of both patients was studied in single CTCs. From 6 single CTC isolated from one patient, 1 CTC had TP53 R110 delC, 1 CTC showed the TP53 R110 delG mutation, and the remaining 4 single CTCs showed the wild type p53 sequence; a pool of 14 CTCs isolated from the same patient also showed TP53 R110 delC mutation. In the tumor breast tissue
Estrogen receptor-negative (ER(-)) breast cancers have limited treatment options and are associated with earlier relapses. Because glucocorticoid receptor (GR) signaling initiates antiapoptotic pathways in ER(-) breast cancer cells, we hypothesized that activation of these pathways might be associated with poor prognosis in ER(-) disease. Here we report findings from a genome-wide study of GR transcriptional targets in a premalignant ER(-) cell line model of early breast cancer (MCF10A-Myc) and in primary early-stage ER(-) human tumors. Chromatin immunoprecipitation with massively parallel sequencing (ChIP-seq) coupled to time-course expression profiling led us to identify epithelial-to-mesenchymal transition (EMT) pathways as an important aspect associated with GR activation. We validated these findings by carrying out a meta-analysis of primary breast tumor gene expression from 1,378 early-stage breast cancer patients with long-term clinical follow-up, confirming that high levels of GR expression
Specific, high affinity receptors for 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] have been demonstrated in human breast cancer cells. In addition, 1,25-(OH)2D3 has been shown to inhibit replication in some human breast cancer cell lines, although the mechanism(s) of this anti-tumor activity remain undefined. There is currently considerable interest in the role of autocrine growth factors in the control of breast cancer cell proliferation and the effects of steroid hormones on their production, receptor binding, and action. Since the epidermal growth factor (EGF) receptor mediates the effects of both EGF and the autocrine growth factor, alpha-transforming growth factor, we investigated the effect of 1,25-(OH)2D3 on EGF receptor levels in several human breast cancer cell lines. Preincubation of T-47D cells with 1,25-(OH)2D3 for 24 h resulted in a significant concentration-dependent decline in the specific binding of [125I]EGF. The effect was observed when EGF binding was assayed at either 0 or 37 degrees C,
Estrogen receptor and progesterone receptor status are routinely assessed using immunohistochemistry assays to assist in patient prognosis and clinical management. Three commonly utilized autostainer vendors-Dako, Leica and Ventana-provide ready-to-use progesterone receptor assays; however, they have never been directly compared in a single breast cancer cohort. We looked at three immunohistochemical progesterone receptor assays, in addition to original ligand-binding assay results, in a single retrospective, tamoxifen-treated breast cancer cohort to investigate inter- and intra-observer agreement, concordance, prognostic ability and measures of test performance. All immunohistochemical assays utilized the manufacturers specified protocols. Five-year disease-free survival was the endpoint of interest, and multivariate models were adjusted for lymph node status, tumor grade, tumor size and human epidermal growth factor 2 status. All assays showed substantial to almost perfect agreement between the three
TY - JOUR. T1 - Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine. T2 - A retrospective population-based time-dependent cohort study. AU - Yang, Szu Pang. AU - Muo, Chih Hsin. AU - Wang, I. Kuan. AU - Chang, Yen Jung. AU - Lai, Shih Wei. AU - Lee, Cynthia Wei Sheng. AU - Morisky, Donald E.. PY - 2015/12/1. Y1 - 2015/12/1. N2 - Aims: We aimed to examine whether morphine treatment is associated with type 2 diabetes mellitus (T2DM) in female breast cancer patients. Methods: We conducted a retrospective cohort analysis of the Longitudinal Health Insurance Database for Catastrophic Illness Patients in Taiwan. A total of 31,112 women with breast cancer without T2DM history during the period 2000-2005 were identified, divided into morphine and non-morphine users (8071 and 23,041 patients, respectively), and the hazard ratios of newly diagnosed T2DM during the period 2005-2010 were calculated. We used a Cox proportional hazard model with time-dependent exposure ...
Objective To evaluate the value of mammographic findings at predicting the presence of an extensive intraductal component (EIC), a major factor in determining breast conserving surgery Methods A prospective study of 348 consecutive mammograms in patients with stage Ⅰ or Ⅱ breast carcinoma, including infiltrating ductal carcinoma ( n =297), ductal carcinoma in situ (DCIS) associated with small invasive foci ( n =8), mucinous carcinoma ( n =21), and medullary carcinoma ( n =22), was performed to determine the predictive value of mammographic features in evaluating the presence or absence of an EIC Results (1) EIC+ cancers were significantly more likely to show the lesion with microcalcifications in comparing with EIC- cases (66 4% vs 20 4%, χ 2=75 29, P 0 001) In particular, the presence of microcalcifications alone was more common for EIC+ cancers than for EIC- cancers (21 1% vs 2 0%, χ 2=52 56, P 0 001) (2) 54 6% of patients in whom mammograms showed only a
AND MATERIALS: From July 1986 to April 1993 the International Breast Cancer Study Group (IBCSG) Trial VI randomly assigned 1554 pre/perimenopausal node-positive breast cancer patients to receive cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for either three consecutive courses on months 1-3, or six consecutive courses on months 1-6, both with or without reintroduction CMF. IBCSG Trial VII randomly assigned 1266 postmenopausal node-positive breast cancer patients to receive tamoxifen for 5 years, or tamoxifen for 5 years with three early cycles of CMF, both with or without three courses of delayed CMF. Both trials allowed a choice of mastectomy, or breast-conserving surgery plus radiation therapy, and both were stratified by type of surgery. Radiotherapy was delayed until the initial block of CMF was completed; 4 or 7 months after surgery for pre/perimenopausal patients, and 2 or 4 months after surgery for postmenopausal patients. Over both trials, 718 eligible patients elected to ...
There is accumulating evidence to suggest that different histological grades of invasive ductal breast carcinomas may have distinct molecular origins and pathogenesis and do not typically progress from one grade group to another (28, 29, 30, 31) . The different grades have different clinical behaviors, and within-grade studies to identify the more aggressive subgroups of these classes of breast tumors would be of great assistance in clinical management. The expression of basal/myoepithelial markers has been observed in a proportion of grade III invasive breast tumors, and the spectrum of basal-like tumors, also recognized by morphology (15 , 32) , molecular cytogenetics (16 , 33) , and expression profiling (18 , 19) , has been associated with poor prognosis (17) . CGH has the advantage of being applied to archival pathology specimens with long-term follow-up as well as being amenable to microdissection strategies to profile the molecular genetic change occurring in a pure population of tumor ...
Single-agent poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved as the first targeted therapy available for patients with BRCA-mutated HER2-negative metastatic breast cancer. This meta-analysis aimed to better evaluate activity, efficacy and safety of single-agent PARPi in this population. A systematic search of Medline, Embase and conference proceedings up to 31 January 2018 was conducted to identify randomised controlled trials (RCTs) investigating single-agent PARPi versus monochemotherapy in patients with BRCA-mutated HER2-negative metastatic breast cancer. Using the random-effect model, we calculated summary risk estimates (pooled HR and OR with 95% CI) for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), any grade and grade 3-4 adverse events (AEs), treatment discontinuation rate and time to deterioration in quality of life (QoL). Two RCTs (n=733) were included. As compared with monochemotherapy, single-agent PARPi significantly ...
Jin, R.,Bay, B.H.,Chow, V.T.K.,Tan, P.H.,Lin, V.C.L. (2000). Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. British Journal of Cancer 83 (3) : 319-323. [email protected] Repository ...
Cisplatin (Csp) is a recurrently used chemotherapeutic drug but its use is inadequate due to undesirable adverse effects. In search of alternative medicine more attention has been given to phytochemicals. Septilin (Spt), a polyherbal drug and its therapeutic potential is huge but there is a scarcity of studies on its cytotoxic potential on cancer cells. The current study was designed to examine the effects of Spt in combination with Csp on human breast adenocarcinoma (MCF-7) and normal human breast epithelial (MCF-10A) cell lines. Cell viability for Spt treated cells was studied using MTT assay. IC50 value of Csp on MCF-7 cells was found to be 10 µg/mL at 24 h. This dose was further used to study the combined effects of Csp with Spt on MCF-7 and MCF-10A cell lines. Maximum cytotoxicity of Spt on MCF-7 cells was observed at Spt 5 µg/mL. The mechanism of Spt induced cytotoxicity was studied using apoptosis assay. Spt did not show any cytotoxic effects on MCF-10 A normal human breast epithelial ...
Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and potentially provide a target for treatment. These findings were reported in Breast Cancer Research.. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are stimulated to grow from exposure to the female hormones estrogen and/or progesterone. Other breast cancers are referred to as HER2-positive, which means that they overexpress the human epidermal growth factor receptor 2, a biologic pathway that is involved in replication and growth of a cell.. Breast cancers, on the other hand, that are not stimulated to grow from exposure to estrogen or progesterone and do not overexpress HER2 (HER2 negative) are called triple-negative breast cancers. Triple-negative breast cancers tend to be more aggressive than other ...
Objective: To analyze the implementation of a switching policy of adjuvant aromatase inhibitor (AI) therapy sequentially after tamoxifen in consecutively treated stage I (T1N0M0) hormone receptor (HR)-positive breast cancer (BC) patients. Methods: The records of 279 consecutive HR-positive BC patients diagnosed between 2002 and 2006 and followed at the Soroka Medical Center were reviewed. Results: Two-hundred-seventeen patients who initially received tamoxifen were suitable for switching and 28 received an AI as initial adjuvant treatment. The switch was accomplished in 82.5% of the 217 patients. Those who switched to an AI had a higher proportion of T1c stage than patients eligible who were not switched, but did not differ in age, histologic grade, or having received chemotherapy. Of the 179 patients who switched, 155 (86.6%) completed at least 4.5-5 years of adjuvant tamoxifen/AI therapy. Eighteen patients discontinued AI therapy prematurely because of toxicity. Conclusions: In this stage I BC ...
Trastuzumab has conferred significant clinical benefits in HER-2-positive breast carcinomas. HER-2 status is determined by immunohistochemistry (IHC) and/or fluorescence in situ hybridisation (FISH), but appropriate assessment of HER2 status remains subject to considerable debate. Data on the health economic impact of HER-2 test strategies are limited. A life-long Markov state transition model was used to assess costs and effectiveness of HER-2 assay strategies (based on IHC, FISH, both combined or FISH confirmation of IHC2+) for a hypothetical cohort of early breast cancer patients from the perspective of the Swiss health system. We compared clinically relevant strategies of predictive testing and subsequent trastuzumab treatment of HER-2-positive patients only. FISH testing was the most cost-effective strategy with an incremental cost-effectiveness ratio of ?12,245 per additional quality-adjusted life-year (QALY) gained, compared to no trastuzumab treatment. The next best strategy was parallel ...
The addition of the targeted therapy onartuzumab to Taxol® (paclitaxel) with or without Avastin® (bevacizumab) does not appear to help control disease or improve survival in patients with metastatic triple-negative breast cancer. These findings were published in the Annals of Oncology.. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are stimulated to grow from exposure to the female hormones estrogen and/or progesterone. Other breast cancers are referred to as HER2-positive, which means that they overexpress the human epidermal growth factor receptor 2, a biologic pathway that is involved in replication and growth of a cell.. Breast cancers, on the other hand, that are not stimulated to grow from exposure to estrogen or progesterone and do not overexpress HER2 (HER2 negative) are called triple-negative breast cancers. Triple-negative breast cancers tend to be more aggressive than other breast cancers and have fewer treatment options because hormonal ...
The use of ultra-diluted natural products in the management of disease and treatment of cancer has generated a lot of interest and controversy. We conducted an in vitro study to determine if products prescribed by a clinic in India have any effect on breast cancer cell lines. We studied four ultra-diluted remedies (Carcinosin, Phytolacca, Conium and Thuja) against two human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231) and a cell line derived from immortalized normal human mammary epithelial cells (HMLE). The remedies exerted preferential cytotoxic effects against the two breast cancer cell lines, causing cell cycle delay/arrest and apoptosis. These effects were accompanied by altered expression of the cell cycle regulatory proteins, including downregulation of phosphorylated Rb and upregulation of the CDK inhibitor p27, which were likely responsible for the cell cycle delay/arrest as well as induction of the apoptotic cascade that manifested in the activation of caspase 7 and cleavage ...
Amphiregulin is a recently described member of the epidermal growth factor family. Primary breast cancers were assessed for expression of amphiregulin by immunochemistry (111 cases), Northern, and/or dot blots (68 cases). Epidermal growth factor and estrogen receptors were measured in all cases. p53 and erbB-2 expression was assessed by immunohistochemistry for most cases. There was no association of these factors with amphiregulin expression, which was detected by immunochemistry in 40 of 111 cases. A significant association of amphiregulin expression assessed by Northern dot blots versus immunochemical staining was seen (P = 0.0016). Expression was not detected in adjacent nontumor tissue by immunochemistry. Amphiregulin was expressed in tumor epithelium, but not stromal or inflammatory cells. Expression was more common in lymph node positive cases (23 of 49; 47%) than lymph node negative cases (11 of 42; 26%; P = 0.04). The coexpression of epidermal growth factor receptor and amphiregulin in 35% of
Two estrogen receptors (ER), ERalpha and ERbeta, are expressed in breast cancer but their role in treatment response is unclear. The overall objective of this study was to determine if the presence of ERbeta protein in breast cancer cell lines is an indicator of a poor prognosis based on cell proliferation. In addition, we determined the effect of estradiol (E2) and selective estrogen receptor modulators (SERMs), such as tamoxifen and genistein, on ERalpha and ERbeta protein regulation, to help in the understanding of the mechanism behind their role in modulating cell proliferation. Using western blot and immunofluorescence analysis, the ER positive cell lines, MCF-7 and T47D, were found to contain both ERalpha and ERbeta, and thus were used as model systems. E2 and genistein, which increased cell proliferation in both cell lines, induced an up regulation of ERbeta in both cell lines. This suggests that an estrogenic response in breast cancer cells is indicated by an increase in ERbeta ...
TY - JOUR. T1 - Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. AU - Hsieh, Chia Chien. AU - Hernández-Ledesma, Blanca. AU - de Lumen, Ben O.. N1 - Funding Information: The authors want to acknowledge the support by the American Institute for Cancer Research (AICR) and the European Commission and the Spanish National Research Council for the Marie-Curie post-doctoral fellowship awarded to Blanca Hernández-Ledesma.. PY - 2010/7. Y1 - 2010/7. N2 - Breast cancer is one of the most common tumors in women of Western countries. The high aggressiveness and therapeutic resistance of estrogen-independent breast tumors have motivated the development of new strategies for prevention and/or treatment. Combinations of two or more chemopreventive agents are currently being used to achieve greater inhibitory effects on breast cancer cells. This study reveals that both aspirin and lunasin inhibit, in a dose-dependent manner, ...
For the eCQM version of this measure, the initial patient population for this measure has been limited to patients with a first recorded breast cancer diagnosis within the past 5 years, as opposed to accounting for that patient population through the use of an exception (as is the case for claims implementation). The numerator captures patients who are prescribed adjuvant tamoxifen or AI, or received adjuvant tamoxifen or AI during the 12 month period. Date of breast cancer diagnosis is defined as date of pathologic diagnosis.. The requirement of Count ,=2 of Encounter, Performed is to establish that the eligible professional has an existing relationship with the patient.. ...
ESMO 2016. Recommended first-line treatments for postmenopausal women with hormone receptor-positive advanced/metastatic breast cancer include third-generation aromatase inhibitors (ie, anastrozole) or tamoxifen. Fulvestrant, is a complete estrogen receptor (ER) antagonist approved for the treatment of ER+ advanced breast cancer after aromatase inhibitors have failed. Although a previous phase 2 study was unable to show a difference in clinical benefit rate (CBR) between first-line fulvestrant and anastrozole in these patients, the median time to progression was significantly increased in patients receiving fulvestrant, which unusually translated into increased overall survival [OS], said Dr Matthew Ellis of Houston, TX, an author of the subsequent FALCON study.. The FALCON study was a phase 3, randomized, double-blind, multicenter trial designed to confirm the superiority of fulvestrant over anastrozole in postmenopausal women with ER+ and/or progesterone receptor-positive (PR+) advanced ...
TY - JOUR. T1 - Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: A molecular and clinicopathological study. AU - de Gonzalo-Calvo, David. AU - López-Vilaró, Laura. AU - Nasarre, Laura. AU - Perez-Olabarria, Maitane. AU - Vázquez, Tania. AU - Escuin, Daniel. AU - Badimon, Lina. AU - Barnadas, Agusti. AU - Lerma, Enrique. AU - Llorente-Cortés, Vicenta. PY - 2015/12/12. Y1 - 2015/12/12. N2 - © 2015 de Gonzalo-Calvo et al. Background: The metabolic effect of intratumor cholesteryl ester (CE) in breast cancer remains poorly understood. The objective was to analyze the relationship between intratumor CE content and clinicopathological variables in human breast carcinomas. Methods: We classified 30 breast carcinoma samples into three subgroups: 10 luminal-A tumors (ER+/PR+/Her2-), 10 Her-2 tumors (ER-/PR-/Her2+), and 10 triple negative (TN) tumors (ER-/PR-/Her2-). We analyzed intratumor neutral CE, free cholesterol (FC) and ...
Many studies done in the 1970s showed that lumpectomy plus radiation to treat women diagnosed with stage I or stage II breast cancer offered the same survival rates as mastectomy. Based on these studies, the U.S. National Institutes of Health released a statement in 1990 saying that lumpectomy plus radiation was preferred over mastectomy to treat early-stage breast cancer. Right now about 60% of women diagnosed with early-stage breast cancer choose lumpectomy followed by radiation. Because the studies were done 40 years ago, researchers wondered if survival rates for lumpectomy plus radiation and mastectomy were still similar and decided to do a new study. The results suggest that women diagnosed with early-stage breast cancer who have lumpectomy followed by radiation have slightly better survival rates than women who have mastectomy alone or mastectomy followed by radiation. While the results seem perplexing, the design of the study may have had something to do with the outcome. The research ...
A striking difference between ER+ and ER- disease is emerging at the level of mRNA expression. Although in ER+ disease a significant number of genes have been found that correlate with clinical outcome [5, 10, 18, 22], in ER- disease no such prognostic signatures have thus far been reported. Moreover, although in ER+ tumors subtypes of different prognostic risks, the luminal A and B subtypes, have been defined [21, 22], no such subdivisions have been noted for ER- breast cancer. It is known that the two main subtypes of ER- breast cancer (ER-/HER2+ and basals) have worse prognosis compared with the luminal A subtype, but no outcome differences between the ER-/HER2+ and basal subtypes have been observed [15, 21-23, 26].. We believe that these differences between ER+ and ER- disease are related to the different histopathologic characteristics of the tumors. The prognostic signatures derived for ER+ breast cancer are characterized by genes related to cell cycle and cell proliferation pathways, and ...
Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue and immune cells from blood and spleen. Using expression quantitative trait loci (eQTL) reported in these tissues, we identify 26 previously unreported, likely target genes of overall breast cancer risk variants, and 17 for estrogen receptor (ER)-negative breast cancer, several with a known immune function. We determine the directional effect of gene expression on disease risk measured based on single and multiple eQTL. In addition, using a gene-based test of association that considers eQTL from multiple tissues, we identify seven (and four) regions with variants associated with overall (and ER-negative) breast cancer risk, which were not reported in previous GWAS. Further investigation of the function of the implicated genes in breast and immune cells may provide insights into ...
TY - JOUR. T1 - Expression of glucocorticoid and progesterone nuclear receptor genes in archival breast cancer tissue. AU - Smith, Robert A.. AU - Lea, Rod A.. AU - Curran, Joanne E.. AU - Weinstein, Stephen R.. AU - Griffiths, Lyn R.. PY - 2002/12/4. Y1 - 2002/12/4. N2 - Background: Previous studies in our laboratory have shown associations of specific nuclear receptor gene variants with sporadic breast cancer. In order to investigate these findings further, we conducted the present study to determine whether expression levels of the progesterone and glucocorticoid nuclear receptor genes vary in different breast cancer grades. Methods: RNA was extracted from paraffin-embedded archival breast tumour tissue and converted into cDNA. Sample cDNA underwent PCR using labelled primers to enable quantitation of mRNA expression. Expression data were normalized against the 18S ribosomal gene multiplex and analyzed using analysis of variance. Results: Analysis of variance indicated a variable level of ...
Margolese RG, Fisher B, Hortobagyi GN, Bloomer WD (2000). "Neoplasms of the Breast". In Bast RC, Kufe DW, Pollock RE, et al. ( ... Mainly taken from risk factors for breast cancer, risk factors can be described in terms of, for example: Relative risk, such ... Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (July 2004). "Breast carcinoma in men: a population-based study". ... of breast cancer cases are diagnosed in women." Increase in incidence in the exposed group, such as "each daily alcoholic ...
Erratum for "Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms"". Science. 259 ( ... 1990). "Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms". Science. 250 (4985): ... Li F.P.; Fraumeni J.F. (October 1969). "Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?". Ann. ... at least one first or second degree relative with an LFS tumour (except breast cancer if the proband has breast cancer) before ...
These were cancers of the brain, lung, bowel, breast, and bladder, and other neoplasms. Not only are benzodiazepines associated ... Breast feeding by mothers using nitrazepam is not recommended. Nitrazepam is a long-acting benzodiazepine with a risk of drug ... Nitrazepam rapidly crosses the placenta and is present in breast milk in high quantities. Therefore, benzodiazepines including ...
Breast cysts (as occur commonly during pregnancy and at other times) are another example, as are other encapsulated glandular ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term 'neoplasm' is a synonym of "tumor". 'Neoplasia' denotes the process of the formation of neoplasms/tumors, the process ... "II Neoplasms". World Health Organization. Retrieved 19 June 2014.. *^ a b Abrams, Gerald. "Neoplasia I". Retrieved 23 January ...
Neoplasms of the Lung Chapter 75: Breast Cancer Chapter 76: Upper Gastrointestinal Tract Cancers Chapter 77: Lower ... Fine Needle Aspiration of Breast Cyst Chapter CP11: Clinical Procedures Tutorial: IV Insertion Chapter CP12: Clinical ... Polycythemia Vera and Other Myeloproliferative Neoplasms Chapter 100: Acute Myeloid Leukemia Chapter 101: Chronic Myeloid ...
", "breast cancer" to "breast neoplasms". Where appropriate, these MeSH terms are automatically "expanded", that is, include ...
Excessive activation of LIM-kinase is displayed in breast cancer. Breast tumor cells with suppressed expression of the LIM- ... The factors limiting the growth of malignant neoplasm include the basal membrane and various components of the surrounding ... of all histological types of breast cancer. Despite the considerable structural diversity of the primary breast tumor, five ... For example, breast tumor cells detached from the solid mass gain the ability to invade lymphatic vessels. Currently, two ...
It also confirms the genetic heterogeneity between the primary neoplasm of breast cancer patients and their respective ... 2003). Models of Breast Cancer: quo vadis, animal modeling? Breast Cancer Research 6(31), 31-38.doi: 10.1186/bcr723 Pulaski BA ... Fantozzi, A; Christofori, G (2006). "Mouse models of breast cancer metastasis". Breast Cancer Research. 8 (4): 212. doi:10.1186 ... Mice may not be an ideal model for breast cancer. This is mainly due to the lack of precision in many of the models. When ...
A urogenital neoplasm is a tumor of the urogenital system. Types include: Cancer of the breast and female genital organs: ( ... Breast cancer, Vulvar cancer, Vaginal cancer, Vaginal tumors, Cervical cancer, Uterine cancer, Endometrial cancer, Ovarian ...
... hCG was discovered to be expressed in certain kinds of malignant neoplasms, including breast cancer, adenocarcinoma of the ... Agnantis, NJ; F Patra; L Khaldi; S Filis (1992). "Immunohistochemical expression of subunit beta HCG in breast cancer". Eur J ...
In 2009, an update including 5 more years (up to 1996) found an increase in "lymphatic and hematopoietic tissue neoplasms" and ... increased breast cancer.[11]. The male children of mothers who were, during pregnancy of those children, exposed to high levels ...
... and clinical evidence of malignant pDC infiltrations in the breasts, eyes, kidneys, lungs, gastrointestinal tract, bone, ... The neoplasm occurs in individuals of all ages but predominates in the elderly; in children, it afflicts males and females ... Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of ... Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy with features of cutaneous lymphoma (e.g. malignant ...
A study of 93 patients with incurable neoplasms". J Natl Med Assoc. 43 (4): 211-240. PMC 2616951. PMID 14850976.. ... In 1951, Jane C. Wright demonstrated the use of methotrexate in solid tumors, showing remission in breast cancer.[35] Wright's ... It is effective for the treatment of a number of cancers, including: breast, head and neck, leukemia, lymphoma, lung, ... Types of cancers it is used for include breast cancer, leukemia, lung cancer, lymphoma, and osteosarcoma.[1] Types of ...
breast cancer metastasis neoplasm chemotherapy Mouse models of breast cancer metastasis Phyllodes tumour "Secondary (metastatic ... advanced breast cancer, secondary tumours, secondaries or stage 4 breast cancer, is a stage of breast cancer where the disease ... Breast Cancer Res Treat 2015. Lee, YT (July 1983). "Breast carcinoma: pattern of metastasis at autopsy". Journal of Surgical ... Metastatic breast cancer cells frequently differ from the preceding primary breast cancer in properties such as receptor status ...
For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers ... They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... Radiation to the breast reduces the ability of that breast to produce milk and increases the risk of mastitis. Also, when ... for breast cancer, see Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. (February 2009). "Breast ...
... (CIS), also known as in situ neoplasm, is a group of abnormal cells.[1][2] While they are a form of neoplasm[ ... This controversy also depends on the exact CIS in question (i.e. cervical, skin, breast). Some authors do not classify them as ... Rather, the lesion is flat (in the skin, cervix, etc.) or follows the existing architecture of the organ (in the breast, lung, ... Other forms require major surgery, the best known being intraductal carcinoma of the breast (also treated with radiotherapy). ...
... s are neoplasms located in the spinal cord. Extradural tumors are more common than intradural neoplasms. Depending ... commonly breast, prostate and lung cancer). Intradural tumours can be classified as intramedullary (within the spinal ...
Lung cancer, breast cancer and melanoma patients were found to be at the highest risk of developing brain metastases. However, ... Neoplasm Metastasis Cancer Brain tumor Tse V (10 November 2009). "Brain Metastasis". Medscape. Retrieved 13 January 2010. " ... The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer. Brain ... However, some cancers such as lymphomas, small cell lung carcinomas (SCLC) and breast cancer may be highly chemosensitive and ...
EMH in the lymph nodes is usually associated with underlying hematopoietic neoplasms. Myeloproliferative neoplasms (MPNs) tend ... The following tissues may also be associated with EMH: thymus, heart, breast, prostate, fatty tissue, adrenal glands, kidney, ... Other manifestations occur in the thymus, heart, breast, prostate, broad ligaments, kidneys, adrenal glands, pleura, ... breast, cervix, nasal sinus, mediastinum and brain. Of the various organs associated with EMH, the spleen offers a unique site ...
Rarer forms of tubal neoplasm include leiomyosarcoma, and transitional cell carcinoma. As the tumor is often enmeshed with the ... and the breast. A pelvic examination may detect an adnexal mass. A CA-125 blood test is a nonspecific test that tends to be ... Primary fallopian tube cancer (PFTC), often just tubal cancer, is a malignant neoplasm that originates from the fallopian tube ...
It is also used to treat breast development and small penis in males. It is typically given as a gel for application to the ... Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DJ (eds ... Androstanolone was found to be effective in the treatment of advanced breast cancer in women in the 1950s, although it was used ... Segaloff A, Horwitt BN, Cakabasi RA, Murison PJ, Osser JV (1955). "Hormonal therapy in cancer of the breast.VIII. The effect of ...
A mammary tumor is a neoplasm originating in the mammary gland. It is a common finding in older female dogs and cats that are ... Szabo S, Haislip A, Garry R (2005). "Of mice, cats, and men: is human breast cancer a zoonosis?". Microsc Res Tech. 68 (3-4): ... There are many differences between mammary tumors in animals and breast cancer in humans, including tumor type, malignancy, and ... Benjamin S, Lee A, Saunders W (1999). "Classification and behavior of canine mammary epithelial neoplasms based on life-span ...
... s are sometimes called breast mice or a breast mouse owing to their high mobility in the breast. Fibroadenomas are ... These tumors characteristically display hypovascular stroma compared to malignant neoplasms. Furthermore, the epithelial ... breast cancer. Complex fibroadenomas may increase the risk of breast cancer. In the male breast, fibroepithelial tumors are ... Fibroadenomas are benign breast tumours characterized by an admixture of stromal and epithelial tissue. Breasts are made of ...
The two most common cancers that spread to the eye from another organ are breast cancer and lung cancer. Other less common ... Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer). Eye cancers can be ... Retrieved from "https://en.wikipedia.org/w/index.php?title=Eye_neoplasm&oldid=895356793" ...
... for breast cancer after breast-conserving surgery, radiotherapy has been found to halve the rate at which the disease recurs.[7 ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... "Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of ... 2005). "Breast cancer". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV (eds.). The GEC ESTRO handbook of brachytherapy. ...
The gene that codes for FAS has been investigated as a possible oncogene.[35] FAS is upregulated in breast cancers and as well ... in ovarian neoplasms predicts shorter survival". Hum. Pathol. 28 (6): 686-92. doi:10.1016/S0046-8177(97)90177-5. PMID 9191002. ... "MRNA stability and overexpression of fatty acid synthase in human breast cancer cell lines". Anticancer Res. 27 (1A): 27-34. ...
Wang S, Wang X, Liu M, Bai O (April 2018). "Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel ... and similar abnormalities in breasts, eyes, kidneys, lungs, gastrointestinal tract, bone, sinuses, ears, and/or testes. The ... Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare type of myeloid cancer in which malignant pDCs infiltrate the ... pDCs that undergo malignant transformation cause a rare hematologic disorder, blastic plasmacytoid dendritic cell neoplasm. In ...
... familial Pancreatic diseases Pancreatic islet cell neoplasm Pancreatic islet cell tumors Pancreatic lipomatosis duodenal ... syndrome Paget disease extramammary Paget disease juvenile type Paget's disease of bone Paget's disease of the breast Paget's ... et varioliformis acuta Pityriasis rubra pilaris Piussan-Lenaerts-Mathieu syndrome Placenta disorder Placenta neoplasm Placental ... retardation-hyperkeratosis Parapsoriasis Parasitophobia Parastremmatic dwarfism Parathyroid cancer Parathyroid neoplasm ...
Such mutations and epigenetic alterations can give rise to cancer (see malignant neoplasms). Thus, CpG island hyper/hypo- ... FEN1 is over-expressed in the majority of cancers of the breast, prostate, stomach, neuroblastomas, pancreatic, and lung. DNA ... "Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers". Mol. Cancer Res. 6 (11): 1710-7. ...
Neoplasms will often show as differently colored masses (also referred to as processes) in CT or MRI results. ... breast cancer, malignant melanoma, kidney cancer, and colon cancer (in decreasing order of frequency). ... The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ... "CNS and Miscellaneous Intracranial and Intraspinal Neoplasms" (PDF). SEER Pediatric Monograph. National Cancer Institute. pp. ...
Myxomas may also occur outside the heart, usually in the skin and breast. Endocrine tumors may manifest as disorders such as ... Epithelioid blue nevus List of cutaneous neoplasms associated with systemic syndromes Carney Syndrome at eMedicine Carney, J.; ... "Pancreatic ductal and acinar cell neoplasms in Carney complex: a possible new association". J Clin Endocrinol Metab. 96 (11): ...
Isabel Woodman, "Breast feeding reduces risk of breast cancer, says study," British Medical Journal, v.); Jul 27, 2002 ... Several severe adverse health effects, such as an increased incidence of cancers, thyroid diseases, CNS neoplasms, and possibly ... The increased radiosensitivity of certain organs in women, such as the breast, ovaries, and thyroid is likely the cause of this ... As increasing concerns are raised regarding the environmental risks related to breast, it is interesting to note that the BEIR ...
Salivary gland neoplasm. *Sarcoma. *Skin cancer. *Small intestine cancer. *Small-cell carcinoma ...
... particularly for breast cancer. The difference between breast cancer recurrence in patients who receive radiotherapy vs. those ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... 2005). "Breast cancer". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium: ... Brachytherapy is commonly used as an effective treatment for cervical,[66] prostate,[67] breast,[68] and skin cancer[69] and ...
Mutations in BRCA1 and BRCA2, important risk factors for ovarian cancer and breast cancer in women, have also been implicated ... "Male Genitals - Prostate Neoplasms". Pathology study images. University of Virginia School of Medicine. Archived from the ... "Breast cancer receives much more research funding, publicity than prostate cancer despite similar number of victims". The Daily ... It also discovered that the waiting time between referral and diagnosis was two weeks for breast cancer but three months for ...
Chronically insufficient intake of folic acid may increase the risk of colorectal, breast, ovarian, pancreas, brain, lung, ... Folate deficiency hinders DNA synthesis and cell division, affecting hematopoietic cells and neoplasms the most because of ...
cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm. *Mucinous cystic neoplasm ... Paget's disease of the breast / Extramammary Paget's disease. Lobular carcinoma. *Lobular carcinoma in situ ...
Secondary neoplasm[edit]. Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur ... A woman being treated with docetaxel chemotherapy for breast cancer. Cold mittens and wine coolers are placed on her hands and ... The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with ... primarily estrogens for breast cancer and androgens for prostate cancer) is known as hormonal therapy, while the inhibition of ...
FEN1 is over-expressed in the majority of cancers of the breast,[32] prostate,[33] stomach,[34][35] neuroblastomas,[36] ... see malignant neoplasms). Thus, CpG island hyper/hypo-methylation in the promoters of DNA repair genes are likely central to ... "Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers". Mol. Cancer Res. 6 (11): 1710-7. ...
"Neoplasms and cancer" has been chosen to reflect the fact that not all tumours are benign. The word "cancer" has been included ... Template:Breast navs(edit talk links history). *Template:Cell navs(edit talk links history) ...
Breast: Nearly all breast cancers are ductal carcinoma.. *Prostate: The most common form of carcinoma of the prostate is ... 8560-8580) Complex epithelial neoplasms. Carcinoma In situ[edit]. The term carcinoma in situ (or CIS) is a term for cells that ... For example, the colon[19] and bladder cancer[20] staging system relies on depth of invasion, staging of breast carcinoma is ... and imaging studies in a logical fashion to obtain information about the size of the neoplasm and the extent of its invasion ...
"Photon-counting breast CT measures up". medicalphysicsweb. Archived from the original on 27 July 2016. Retrieved 28 July 2016. ... superior information as compared to CT scans when seeking information about headache to confirm a diagnosis of neoplasm, ... Some early research has found the dose reduction potential of photon counting CT for breast imaging to be very promising.[116] ...
The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ... breast cancer, malignant melanoma, kidney cancer, and colon cancer (in decreasing order of frequency). ... "CNS and Miscellaneous Intracranial and Intraspinal Neoplasms" (PDF). SEER Pediatric Monograph. National Cancer Institute. pp. ... More generally a neoplasm may cause release of metabolic end products (e.g., free radicals, altered electrolytes, ...
For instance, CMF-therapy for breast cancer (where the cumulative dose is typically less than 20 grams of cyclophosphamide) ... Bernatsky S, Clarke AE, Suissa S (February 2008). "Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis ... breast cancer, small cell lung cancer, neuroblastoma, and sarcoma.[4] As an immune suppressor it is used in nephrotic syndrome ... Myeloproliferative neoplasms, including acute leukemia, non-Hodgkin lymphoma and multiple myeloma, occurred in 5 of 119 ...
The authors also found that EMT can happen in breast cancer cell lines with hypermethylation of CDH1 promoter, but in breast ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ... Inactivation of CDH1 (accompany with loss of the wild-type allele) in 56% of lobular breast carcinomas.[54][55] ... Hajra KM, Chen DY, Fearon ER (March 2002). "The SLUG zinc-finger protein represses E-cadherin in breast cancer". Cancer ...
en:Neoplasm (40) → 신생물 *en:Nephrotic syndrome (38) → 신증후군 *en:Nervous system disease (4) ... en:Breast cancer screening (2). *en:Breathing gas (17). *en:Bronchiectasis (33) → 기관지확장증 ...
টেমপ্লেট:Diseases of the pelvis, genitals and breasts *দে. *স. যৌনবাহিত সংক্রমণ অথবা যৌনব্যাধি-সংক্রান্ত রোগ (STD and STI) ( ...
... s are sometimes called breast mice or a breast mouse owing to their high mobility in the breast.[3] ... These tumors characteristically display hypovascular stroma compared to malignant neoplasms.[2][12][9] Furthermore, the ... Not to be confused with Fibrocystic breast changes.. Fibroadenomas are benign breast tumours characterized by an admixture of ... Since both fibroadenomas, and breast lumps as a sign of breast cancer can appear similar, it is recommended to perform ...
... breast cancer that has spread to the lung is called metastatic breast cancer. Metastases often have a characteristic round ... Horn, L; Lovly, CM; Johnson, DH (2015). "Chapter 107: Neoplasms of the lung". In Kasper, DL; Hauser, SL; Jameson, JL; Fauci, AS ... This makes it the most common cause of cancer-related death in men and second most common in women after breast cancer.[19] The ... and is second after breast cancer in mortality. In 2012, there were 1.82 million new cases globally, and 1.56 million deaths ...
... for breast cancer after breast-conserving surgery, radiotherapy has been found to halve the rate at which the disease recurs.[7 ... Hypopituitarism commonly develops after radiation therapy for sellar and parasellar neoplasms, extrasellar brain tumours, head ... "Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of ... 2005). "Breast cancer". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV (eds.). The GEC ESTRO handbook of brachytherapy. ...
Lung cancer is an extremely heterogeneous family of malignant neoplasms,[1] with well over 50 different histological variants ... similar to breast carcinomas[32] However, it is at present unknown whether blockade of these receptors affects the growth of c- ...
Srikumar Chakravarthi; Baba Krishnan; Malathy Madhavan (1999). "Apoptosis and expression of p53 in colorectal neoplasms". ... "Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: ... As summarized in the articles Carcinogenesis and Neoplasm, for sporadic cancers in general, a deficiency in DNA repair is ...
Glandular and epithelial neoplasms (ICD-O 8010-8589). Epithelium. Papilloma/carcinoma. (8010-8139). *Small cell carcinoma ... Paget's disease of the breast / Extramammary Paget's disease. Lobular carcinoma. *Lobular carcinoma in situ ...
Diseases of the skin include skin infections and skin neoplasms (including skin cancer).[28] ... Mammillated: with rounded, breast-like projections. *Reticular or reticulated: resembling a net ...
Adipose tissue neoplasm. *Adiposis dolorosa. *Adiposogenital dystrophy. *Adipsia. *Adjustment disorder. *Adnexal and skin ...
breast neoplasms. *tamoxifen, pharmacology and therapeutic use. *tamoxifen, antagonists and inhibitors. *cytochrome P-450 2D6 ... Using the Danish Breast Cancer Cooperative Group Registry, we identified 366 cases with local or distant breast cancer ... No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications. Thomas P. ... We computed the breast cancer recurrence odds ratio (OR) and 95% confidence interval for each medication. The pooled recurrence ...
Breast Neoplasms 12 complications 9 Breast 9 Cancer 6 methods 5 Complications more ... 5 prevention & control 4 Treatment 4 ... Bone Neoplasms 1 Bone metastasis 1 Classification 1 Cognitive Behavioral Therapy 1 Colon (Anatomy) 1 Colorectal Neoplasms 1 ... Showing 1 - 12 results of 12 for search Breast Neoplasms complications. Skip to content Breast Neoplasms complications., query time: 0.35s ...
Your purchase of our Breast Cancer cell is supporting NBCFs early detection, education and support services.,br,,br,10% of the ... Breast Cancer affects 1 in every 8 women, but early detection and proper screening can help ensure the best outcomes. This ... Breast Cancer (Malignant neoplasm). Breast Cancer (Malignant neoplasm) GMUS-PD-0104 $8.95 ... All about Breast Cancer (Malignant neoplasm). FACTS: Breast cancer usually begins as a lump that can be seen in a mammogram or ...
Neoplasms of the Breast - Breast cancer is the most common malignancy in women in the United States, with more than 180,000 ... Breast Cancer definition, Diagnosis and Staging, Differential Diagnosis, Treatment and Management. ... And when this process takes place in the breast, its breast cancer. Tumors in the breast tend to grow slowly; by the time a ... What is breast cancer?. Jan 10.2012 Breast cancer is a disease in which malignant (cancer) cells form in the tissues of the ...
... and medullary neoplasms are three common forms of breast cancer. These tumors are differentiated by location and require ... Breast density: Breasts are considered "dense" when there is a high ratio of tissue to fat. Women with dense breasts are more ... Cystic, Mucinous & Serous Neoplasms. Dermoid Cyst. Desmoplastic Small Round Cell Tumor. Ductal, Lobular & Medullary Neoplasms. ... Ductal, lobular, and medullary neoplasms are three of the main types of breast cancer. ...
Search of: Recruiting, Not yet recruiting, Available Studies , Inflammatory Breast Neoplasms - Modify Search. Fill in any or ...
disease or metastatic breast.. - Must be appropriate to receive endocrine therapy as treatment for advanced disease. ( ... In Postmenopausal Women With Locally Advanced Or Metastatic Breast Cancer. Trial Phase:. Phase 2. Minimum Age:. 18 Years. ... In Postmenopausal Women With Locally Advanced Or Metastatic Breast Cancer ...
This a subset of snomed-ct regarding neoplasm and hamartoma, based on Snomed clinical practices used terms (Fondazione S. ...
Male Breast Neoplasms anonymous support group with inform... ... people sharing true stories in the I Have Male Breast Neoplasms ... Do You Have Male Breast Neoplasms? Join friendly ... I Have Male Breast Neoplasms does not have any stories yet. Be ... Male Breast Neoplasms anonymous support group with information on diagnosis, treatment, symptoms, along with personal stories ... and experiences with Male Breast Neoplasms. Youre not alone. Report Group. ...
Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer. *Malignant Neoplasm of Breast ... Comparison of the Breast Tumor Microenvironment. *Triple Negative Breast Cancer. *Hormone Receptor Positive Malignant Neoplasm ... Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR. *Breast Neoplasms ... Phase 1 Study of DS-8201a in HER-2 Breast Cancer Patients. *Malignant Neoplasm of Breast ...
Trastuzumab Completed Phase 1 Trials for Neoplasms, Breast Treatment. Back to Trastuzumab ... MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer. *Trastuzumab ( ... A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer. *Trastuzumab (DB00072) ... in Patients With HER2-positive Advanced Breast Cancer.. *Afatinib (DB08916) ...
The observed bimodal patterns of breast cancer incidence in the U.S. suggested that breast cancer may be viewed as more than ... Leukocyte telomere length, breast cancer risk in the offspring: the relations with fathers age at birth.  Arbeev, Konstantin ... Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.  Kravchenko, J; Akushevich, Igor; ... Optimized approach to decision fusion of heterogeneous data for breast cancer diagnosis.  Jesneck, JL; Nolte, LW; Baker, JA; ...
Breast Neoplasms (Breast Cancer). 2/2016. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian ... Evaluating 17 breast cancer susceptibility loci in the Nashville breast health study.. ... Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization.. ... Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression.. ...
Trastuzumab Terminated Phase 2 Trials for Cancer, Breast / Neoplasms Metastasis Treatment. Back to Trastuzumab ... Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery. *Everolimus ( ... A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer. ... Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer. *Trastuzumab ...
Find out information about Breast neoplasms. cancer cancer, in medicine, common term for neoplasms, or tumors, that are ... Like benign tumors, malignant tumors do not respond to body mechanisms... Explanation of Breast neoplasms ... OR breast neoplasms [Figure/Table Caption] OR breast neoplasms[Body - All Words] OR breast neoplasms[Title] OR breast neoplasms ... breast cancer. (redirected from Breast neoplasms). Also found in: Dictionary, Thesaurus, Medical. breast cancer,. cancercancer, ...
Breast Neoplasms (Breast Cancer). 11/2015. Response to preoperative endocrine therapy in breast cancer patients can alter ... Spotlight on neoadjuvant therapy for breast cancer.. 5/2015. Surgical Considerations After Neoadjuvant Chemotherapy: Breast ... Utilization and Outcomes of Breast Brachytherapy in Younger Women.. 8/2015. GATA-binding protein 3 enhances the utility of ... Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult ...
Breast cancer and other second neoplasms after childhood Hodgkins disease. Bhatia S, Robison LL, Oberlin O, et al.. Abstract: ... Systematic screening for breast cancer could be important in the health care of such women.. This is a service of:. Rheinische ... The risk of solid tumors, especially breast cancer, is high among women who were treated with radiation for childhood Hodgkins ... Patients who survive Hodgkins disease are at increased risk for second neoplasms. As survival times increase, solid tumors are ...
Comparative performance of multiview stereoscopic and mammographic display modalities for breast lesion detection.  Webb, LJ; ... Browsing Masters Theses by Subject "Breast Neoplasms". 0-9. A. B. C. D. E. F. G. H. I. J. K. L. M. N. O. P. Q. R. S. T. U. V. W ...
intra-lobular (epithelial and stromal) inter-lobular breast lymphoma metastasis to breast Intralobular an... ... There are many types of breast neoplasms, which can be divided into the following broad oversimplified categories as a starting ... breast pathology *malignant lesions* breast cancer *breast adenocacrinoma *ductal breast carcinoma * ductal carcinoma in situ ( ... Breast within a breast sign in hamartomaBreast within a breast sign in hamartoma ...
Keywords : intestinal obstruction; secondary; breast neoplasms; carcinoma; abdomen; acute. · abstract in Portuguese · text in ... Intestinal obstruction due to malign breast neoplasm and peritoneal carcinomatosis: a case report. J. Coloproctol. (Rio J.) [ ... A case of colonic obstruction due to carcinomatosis secondary to breast cancer is reported, emphasizing its diagnostic aspects ... Peritoneal carcinomatosis due to breast cancer is rare and gastrointestinal tract involvement is also unusual. Symptoms are ...
Breast neoplasms Tier 1 H96. Breast neoplasms Tier 2 H96. Breast neoplasms Tier 3 H96. Breast neoplasms Tier 4 H96. Breast ... Breast neoplasms Tier 1 M96. Breast neoplasms Tier 2 M96. Breast neoplasms Tier 3 M96. Breast neoplasms Tier 4 M96. Breast ... Breast neoplasms Tier 1-4 H384 Predesigned 384-well panel for use with SYBR® Green ... Breast neoplasms Tier 1-4 M384 Predesigned 384-well panel for use with SYBR® Green ...
... a novel and reproducible method for possible ancillary proteomic pattern expression of breast neoplasms by SELDI-TOF Mod Pathol ... Excised fresh breast tissue for evaluation and/or treatment of a variety of breast lesions were sampled by FNA technique and ... In conclusion, FNA of breast tissue placed in PreservCyt is a potentially acceptable method of sample handling for evaluation ... Preliminary results from a spectrum of breast lesions suggest these patterns may have potential for ancillary testing for ...
Prevalence of risk factors for breast neoplasm in the city of Maringá, Paraná state, Brazil1 ... As for the family history of breast cancer, 2.3% (10) of the women reported that their mother has or had breast cancer. When ... This risk increases when the relative has breast cancer before the age of 50 years and in both breasts(15). ... with breast cancer(3). In both studies, a small number of women had some first-degree relatives with breast cancer, like in the ...
Malignant neoplasm of prostate , Colorectal Cancer , Integration of Cancer Health Activities Into African American Churches ... breast, prostate, colorectal) delivered through trained and certified lay peer community health advisors in African American ...
Find doctors who treat Malignant Neoplasm of Female Breast near Washington, DC and accept WebMD.PhysicianDirectory.Types. ... Malignant Neoplasm of Female Breast. Female breast cancer (malignant neoplasm of female breast) occurs when abnormal cells ... Physicians Who Treat Malignant Neoplasm of Female Breast Who Accept CDPHP New York State of Health - Small Business Near ... These cancer cells can grow uncontrollably and spread outside the breast, usually through the lymph nodes or through the blood ...
Find doctors who treat Malignant Neoplasm of Female Breast near Washington, DC and accept WebMD.PhysicianDirectory.Types. ... Malignant Neoplasm of Female Breast. Female breast cancer (malignant neoplasm of female breast) occurs when abnormal cells ... Physicians Who Treat Malignant Neoplasm of Female Breast Who Accept Highmark Blue Cross Blue Shield Shared Cost 1500, a Multi- ... These cancer cells can grow uncontrollably and spread outside the breast, usually through the lymph nodes or through the blood ...
Higher-Than-Expected Incidence of Marrow Neoplasms After Adjuvant Therapy for Breast Cancer. By Matthew Stenger. May 25, 2015. ... Patients developing marrow neoplasms were significantly older than those who did not at the time of breast cancer diagnosis ( ... 1. Wolff AC, Blackford AL, Visvanathan K, et al: Risk of marrow neoplasms after adjuvant breast cancer therapy: The National ... The median time to diagnosis of marrow neoplasms after breast cancer diagnosis was 4.9 years. Overall survival after diagnosis ...
Investigational Drugs with Clinical Trials for: Breast Neoplasms. ✉ Send this page by email. Email this page to a colleague ...
C50.12 Malignant neoplasm of central portion of breast, male C50.121 Malignant neoplasm of central portion of right male breast ... C50.212 Malignant neoplasm of upper-inner quadrant of left female breast C50.219 Malignant neoplasm of upper-inner quadrant of ... C50.22 Malignant neoplasm of upper-inner quadrant of breast, male C50.221 Malignant neoplasm of upper-inner quadrant of right ... C50.222 Malignant neoplasm of upper-inner quadrant of left male breast C50.229 Malignant neoplasm of upper-inner quadrant of ...
We report on and discuss a case of a female patient diagnosed with breast cancer in 1996, which was histopathologically ... Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer. ... "Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer". ... "Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer." ...
Study aims were to evaluate the correlation between some risk factors and womens attendance to breast checkups, and to assess ... introduction and objective: In Poland, consulting is offered to women about risk factors of breast cancer, breast symptoms and ... Selected breast cancer risk factors and early detection of the neoplasm in women from Lublin region attending screening program ... The frequency of breast checkups (mammography, CBE and BSE) and occurrence of breast cancer risk factors in studied women were ...
  • Breast Cancer (Malignant neoplasm) under a microscope! (giantmicrobes.com)
  • Breast Cancer affects 1 in every 8 women, but early detection and proper screening can help ensure the best outcomes. (giantmicrobes.com)
  • Your purchase of our Breast Cancer cell is supporting NBCF's early detection, education and support services. (giantmicrobes.com)
  • FACTS: Breast cancer usually begins as a lump that can be seen in a mammogram or felt when the breast is examined. (giantmicrobes.com)
  • However, risk-factors that increase the probability of developing the disease include a family history of breast or ovarian cancer, increasing age, never having breastfed, never having given birth, long-term hormone replacement therapy, and smoking. (giantmicrobes.com)
  • Men can get breast cancer, too. (giantmicrobes.com)
  • Although breast cancer is extremely serious, most people (approximately 80%) who get it survive, particularly if treatment is initiated early in the course of the disease before it has spread from its original site. (giantmicrobes.com)
  • Breast cancer is a cellular disease caused by uncontrolled division of abnormal cells in breast tissue. (giantmicrobes.com)
  • What is breast cancer? (health.am)
  • Breast cancer is a disease in which malignant (cancer) cells form in the tissues of the breast. (health.am)
  • And when this process takes place in the breast, it's breast cancer. (health.am)
  • It is important to bear in mind that not all families with a pedigree suggestive of hereditary breast cancer are linked to BRCA1 or BRCA2. (health.am)
  • Fatty acids in the breast may be useful indicators of cancer in postmenopausal women, according to a new study published online in the journal Radiology. (health.am)
  • The results may help researchers determine the underlying mechanisms behind breast cancer development in some patients. (health.am)
  • Ductal, lobular, and medullary neoplasms are three of the main types of breast cancer . (knowcancer.com)
  • Doctors have established a genetic link in about 5% of breast cancer cases, so a family history of cancer can put one at risk. (knowcancer.com)
  • Women who got their periods before age 12, or enter menopause after 55, are more at risk of developing breast cancer. (knowcancer.com)
  • Breast cancer is more common in women who have their first full-term pregnancy after age 30. (knowcancer.com)
  • Women who have received radiation treatments to the chest, particularly when during breast development, are more likely to get breast cancer later on. (knowcancer.com)
  • Women who have been on hormone therapy or birth control pills for four or more years have a higher risk of breast cancer. (knowcancer.com)
  • Women with dense breasts are more likely to get breast cancer, although doctors aren't sure why. (knowcancer.com)
  • The first sign of breast cancer is usually a painless lump or thickening in the breast. (knowcancer.com)
  • Also searched for Breast Cancer and Breast carcinomas . (clinicaltrials.gov)
  • Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer. (drugbank.ca)
  • A recessive variant of XRCC4 predisposes to non- BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. (duke.edu)
  • PURPOSE: To define the biology driving the aggressive nature of breast cancer arising in young women. (duke.edu)
  • An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. (duke.edu)
  • Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. (duke.edu)
  • The observed bimodal patterns of breast cancer incidence in the U.S. suggested that breast cancer may be viewed as more than one biological entity. (duke.edu)
  • Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. (duke.edu)
  • Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials. (duke.edu)
  • ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer. (curehunter.com)
  • Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. (curehunter.com)
  • Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. (curehunter.com)
  • Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes. (curehunter.com)
  • Evaluating 17 breast cancer susceptibility loci in the Nashville breast health study. (curehunter.com)
  • Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. (curehunter.com)
  • Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes. (curehunter.com)
  • Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. (curehunter.com)
  • A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy. (drugbank.ca)
  • Breast cancer is the second leading cause of cancer death in women (following lung cancer lung cancer, cancer that originates in the tissues of the lungs. (thefreedictionary.com)
  • Although the vast majority of the cases occur in women, some men also get breast cancer. (thefreedictionary.com)
  • Even allowing for improvements in detection (i.e., the introduction of routine mammography), there has been a long-term gradual increase in the incidence of breast cancer since the early 1970s, but because of the more effective treatment afforded by such early detection, overall mortality began to decrease by the mid-1990s. (thefreedictionary.com)
  • Epidemiological study has identified certain risk factors that increase the possibility that a woman will get breast cancer, although not all women with breast cancer have these traits, and many women with all of these traits do not develop the disease. (thefreedictionary.com)
  • and a history of breast cancer or benign proliferative breast disease. (thefreedictionary.com)
  • a coincident drop in the incidence of breast cancer tumors, especially estrogen-positive tumors, which apparently could not be accounted for by other causes, strongly suggested a link between the two. (thefreedictionary.com)
  • About 5% of women with breast cancer have an inherited susceptibility to the disease, and most of these women have an inherited mutation in one of two genes. (thefreedictionary.com)
  • In 1994 it was discovered that women who inherit a mutated BRCA1 gene have an almost 85% chance of developing breast cancer and an increased chance of developing uterine cancer. (thefreedictionary.com)
  • The defective gene can be inherited from either parent, but appears to cause breast cancer only in women. (thefreedictionary.com)
  • Young women who get breast cancer often come from families that carry a BRCA1 mutation. (thefreedictionary.com)
  • Response to preoperative endocrine therapy in breast cancer patients can alter surgical and chemotherapy options. (curehunter.com)
  • GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. (curehunter.com)
  • Spotlight on neoadjuvant therapy for breast cancer. (curehunter.com)
  • Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). (curehunter.com)
  • Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. (curehunter.com)
  • Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. (curehunter.com)
  • 2000 cGy) of radiation (relative risk, 5.9) were associated with significantly increased risk of breast cancer. (uni-bonn.de)
  • The risk of solid tumors, especially breast cancer, is high among women who were treated with radiation for childhood Hodgkin's disease. (uni-bonn.de)
  • Systematic screening for breast cancer could be important in the health care of such women. (uni-bonn.de)
  • Solitary peripheral papilloma of the breast: a radiologic-pathologic correlation of a benign lesion that may mimic breast cancer on mammography. (radiopaedia.org)
  • Peritoneal carcinomatosis due to breast cancer is rare and gastrointestinal tract involvement is also unusual. (scielo.br)
  • Investigation of carcinomatosis origin is mandatory as breast cancer carcinomatosis can relieve partially or totally with chemo and hormonal therapy. (scielo.br)
  • A case of colonic obstruction due to carcinomatosis secondary to breast cancer is reported, emphasizing its diagnostic aspects and treatment. (scielo.br)
  • The aim of this study was to identify the prevalence of the risk factors for breast cancer among women between 40 and 69 years old in the city of Maringá, Paraná State, Brazil. (scielo.br)
  • Of all cancer types, breast tumors stand out among women, as observed by the frightening statistics. (scielo.br)
  • Estimates for 2008 in Brazil, valid for 2009 as well, indicate 466,730 new cases of cancer and one of the most incident types among women is breast cancer, with an estimated number of 49,400 new cases (50.71/100,000 women). (scielo.br)
  • Breast tumors are the most frequent type of cancer among women in the South of Brazil, totaling an estimated risk of 67/100,000 women. (scielo.br)
  • In Paraná, 2970 new cases of breast cancer (56.7/100,000 women) occurred in 2006. (scielo.br)
  • Until date, breast cancer cannot be avoided, but some risk factors of the disease have already been discovered, which can facilitate early detection and contribute to cancer screening (3) . (scielo.br)
  • The most discussed risk factors are the woman s age and family history, that is, having a first-degree relative with breast cancer (4) . (scielo.br)
  • Incidence levels of breast cancer increase rapidly until the age of 50, after which the increase continues at a slower pace (1) . (scielo.br)
  • In scientific terms, there are no specific strategies that permit primary breast cancer prevention, although its incidence can be decreased through health promotion actions, emphasizing attention with risk factors, including obesity and smoking (5) . (scielo.br)
  • In view of this problem, this research intended to identify the prevalence of risk factors for breast cancer in women between 40 and 69 years, in Maringá, PR. (scielo.br)
  • This age range was chosen due to the greater prevalence of illness and death by breast cancer in the age range between 40 and 69 years (5) . (scielo.br)
  • Project HEAL is a series of three cancer early detection workshops (breast, prostate, colorectal) delivered through trained and certified lay peer community health advisors in African American churches. (centerwatch.com)
  • Female breast cancer (malignant neoplasm of female breast) occurs when abnormal cells develop in the breast. (webmd.com)
  • These cancer cells can grow uncontrollably and spread outside the breast, usually through the lymph nodes or through the blood stream. (webmd.com)
  • In a study reported in the Journal of Clinical Oncology , Antonio C. Wolff, MD , of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues found a low but higher-than-expected incidence of marrow neoplasms in patients receiving adjuvant radiation therapy or chemotherapy for breast cancer. (ascopost.com)
  • The study used the National Comprehensive Cancer Network Breast Cancer Outcomes Database to evaluate the frequency of marrow neoplasms among 20,063 patients with stage I to III breast cancer treated at U.S. academic centers between 1998 and 2007. (ascopost.com)
  • Patients developing marrow neoplasms were significantly older than those who did not at the time of breast cancer diagnosis (median = 59.1 vs 53.9 years, P = .03). (ascopost.com)
  • The median time to diagnosis of marrow neoplasms after breast cancer diagnosis was 4.9 years. (ascopost.com)
  • As noted by the authors, a 2003 report from the National Surgical Adjuvant Breast and Bowel Project indicated an 8-year cumulative incidence of MDS or AML of 0.27% among breast cancer patients receiving doxorubicin and cyclophosphamide. (ascopost.com)
  • Family history of cancer and marrow cytogenetics were available for 41 of the patients with marrow neoplasms. (ascopost.com)
  • 19 (59%) of the 32 patients with a family history of cancer had at least one first- or second-degree relative with breast or ovarian cancer. (ascopost.com)
  • BackgroundSeveral accomplishments have been achieved in triple-negative breast cancer (TNBC) research over the last year. (semanticscholar.org)
  • Recent therapeutic trends and promising targets in triple negative breast cancer. (semanticscholar.org)
  • Targeting the PI3-kinase pathway in triple negative breast cancer. (semanticscholar.org)
  • Triple negative breast cancer (TNBC) is characterised by poor outcomes and a historical lack of targeted therapies. (semanticscholar.org)
  • BACKGROUND Standard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. (semanticscholar.org)
  • Abstract Breast cancer is the most prevalent cancer among women worldwide. (semanticscholar.org)
  • Struk-Panfill M, Błaut K, Pęksa R, Kmieć P, Sworczak K. Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer. (termedia.pl)
  • We report on and discuss a case of a female patient diagnosed with breast cancer in 1996, which was histopathologically assessed as an invasive ductal carcinoma. (termedia.pl)
  • Due to unknown primary site of the metastasis and given the patient's history of breast cancer, it was suspected that the breast cancer was in fact a neuroendocrine tumour. (termedia.pl)
  • In Poland, consulting is offered to women about risk factors of breast cancer, breast symptoms and early cancer detection. (aaem.pl)
  • Study aims were to evaluate the correlation between some risk factors and women's attendance to breast checkups, and to assess links between risk factors and detection of early breast cancer. (aaem.pl)
  • The study involved 8014 women aged 50-69 years, participating in breast cancer screening program. (aaem.pl)
  • The frequency of breast checkups (mammography, CBE and BSE) and occurrence of breast cancer risk factors in studied women were evaluated as well as clinical stage of detected tumors. (aaem.pl)
  • Odds ratios were used to compare relative odds of breast cancer with exposure to risk factors. (aaem.pl)
  • There were no significant links between most risk factors and odds of early stages of breast cancer. (aaem.pl)
  • Women should have preventive checkups irrespective of their breast cancer risk factors. (aaem.pl)
  • Estrogen carcinogenesis in breast cancer. (aaem.pl)
  • Beiki O, Hall P, Ekbom A, Moradi T. Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: a population-based cohort study. (aaem.pl)
  • Gareth D, Evans R, Howell A. Breast cancer risk-assessment models. (aaem.pl)
  • Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models. (aaem.pl)
  • Active Smoking and Breast Cancer Risk: Original Cohort Data and Meta-Analysis. (aaem.pl)
  • Pięta B, Chmaj-Wierzchowska K, Opala T. Life style and risk of development of breast and ovarian cancer. (aaem.pl)
  • Meads C, Ahmed I, Riley RD. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. (aaem.pl)
  • Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. (aaem.pl)
  • to understand the meaning of work activities for young women with breast cancer . (bvsalud.org)
  • interviewed from the guiding question how is it for you to be young with breast cancer , in relation to work ? (bvsalud.org)
  • Four patients had a known history of breast cancer (remote in 3 and concurrent in 1), but the metastases (3 liver, 1 lung) labeled for chromogranin and/or synaptophysin, prompting misdiagnosis as neuroendocrine neoplasm. (elsevier.com)
  • an occult concurrent primary breast cancer (PBC) was subsequently identified as the source. (elsevier.com)
  • In conclusion, although neuroendocrine differentiation is uncommon in breast cancer and does not commonly increase in metastases, MBC with neuroendocrine differentiation should be considered in patients with visceral neuroendocrine neoplasms of unknown primary site. (elsevier.com)
  • Cervical cancer and breast cancer are leading causes of cancer-related morbidity and mortality in Costa Rica. (paho.org)
  • Tumors or cancer of the human BREAST. (uchicago.edu)
  • Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. (uchicago.edu)
  • Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. (uchicago.edu)
  • The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. (uchicago.edu)
  • Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. (uchicago.edu)
  • the COVID-19 pandemic breast cancer consortium. (uchicago.edu)
  • In addition, these results suggest that the initiating oncogenic events determine the morphologic features associated with cancer progression because EMT is observed only in certain types of neoplasm. (biomedcentral.com)
  • Transgenic mouse models of mammary cancer have added considerably to our knowledge of human breast tumorigenesis. (biomedcentral.com)
  • 12 A breast cancer that arises from myoepithelial cells, which are a normal constituent of the salivary acini and ducts and are found between the epithelial cells and the basement membrane. (malacards.org)
  • The incidence of DCIS has increased with the development of mammography screening for breast cancer. (wikidot.com)
  • This article provides an overview for radiologists, with a focus on breast cancer . (pacs.de)
  • For a summary article for medical students and non-radiologists, see breast cancer (summary) . (pacs.de)
  • Breast cancer is the most common nonskin malignancy in women. (pacs.de)
  • Enhanced anti-tumor and anti-metastasis therapy for triple negative breast cancer by CD44 receptor-targeted hybrid self-delivery micelles. (mazenz.com)
  • Related Articles Enhanced anti-tumor and anti-metastasis therapy for triple negative breast cancer by CD44 receptor-targeted hybrid self-delivery micelles. (mazenz.com)
  • Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer. (mazenz.com)
  • Related Articles Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer. (mazenz.com)
  • The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic "master regulators" of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis. (usda.gov)
  • Regional differences in surgical management of breast cancer. (doctorasyou.com)
  • Global breast cancer mortality statistics. (doctorasyou.com)
  • Using a population-based cancer reporting system to evaluate a breast cancer detection and awareness program. (doctorasyou.com)
  • Local excision and primary radiation therapy for early breast cancer. (doctorasyou.com)
  • Response: the case for the two-step biopsy procedure for breast cancer. (doctorasyou.com)
  • American Society of Clinical Oncology clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. (blogspot.com)
  • The role of IMRT in breast cancer. (blogspot.com)
  • Breast cancer screening clinical practice guideline. (blogspot.com)
  • Adjuvant ovarian ablation in the treatment of premenopausal women with early stage invasive breast cancer. (blogspot.com)
  • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (blogspot.com)
  • Zoledronic acid as adjuvant therapy in combination with adjuvant endocrine therapy for premenopausal women with early-stage hormone receptor positive breast cancer. (blogspot.com)
  • 1) Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. (blogspot.com)
  • The prophylactic use of filgrastim in patients with breast cancer. (blogspot.com)
  • The continued use of trastuzumab beyond disease progression in patients with metastatic breast cancer. (blogspot.com)
  • The use of bevacizumab in metastatic breast cancer. (blogspot.com)
  • UICC multidisciplinary project on breast cancer : reports of the four meetings held at Leeds Castle (Kent, UK in 1980, 1981, and 1982. (who.int)
  • Breast cancer : epidemiology, endocrinology, biochemistry and pathobiology / Helmuth Vorherr. (who.int)
  • Primary management of breast cancer : alternatives to mastectomy / edited by Jeffrey S. Tobias and Michael J. Peckham. (who.int)
  • Prevention of breast cancer / Ian S. Fentiman. (who.int)
  • Breast and gynecologic cancer epidemiology / authors, Jennifer L. Kelsey, Nancy G. Hildreth. (who.int)
  • Oral contraceptives & breast cancer / Committee on the Relationship between Oral Contraceptives and Breast Cancer, Institute of Medicine, Division of Health Promotion and Disease Prevention. (who.int)
  • Patient no more : the politics of breast cancer / Sharon Batt. (who.int)
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. (blogspot.com)
  • ACR Appropriateness Criteria® stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. (blogspot.com)
  • Ki-67 and IHC4) in early-stage breast cancer. (blogspot.com)
  • Medications for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force recommendation statement. (blogspot.com)
  • Treatment of primary breast cancer. (blogspot.com)
  • Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. (blogspot.com)
  • Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy. (blogspot.com)
  • Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. (blogspot.com)
  • NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. (blogspot.com)
  • Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. (blogspot.com)
  • International Copenhagen Symposium on Detection of Breast Cancer (3rd : 1985). (phsa.ca)
  • The incidence of multiple primary malignant neoplasms increases with age, reflecting an increase in overall cancer risk in older patients. (biomedcentral.com)
  • He did have a family history of malignancy though, as his father had developed rectal cancer and his sister had a kidney neoplasm. (biomedcentral.com)
  • Breast cancer is an uncontrollable growth of abnormal cells in different areas of the chest. (ac.ir)
  • Research about the causes of breast cancer is crucial. (ac.ir)
  • Researchers have submitted further evidences about the relationship between some of the chemical used in home environment and breast cancer. (ac.ir)
  • Although there are not conclusive evidences to prove the role of certain chemicals for increasing the risk of breast cancer, there are many reasons for increasing concerns in this area that will be discussed in details. (ac.ir)
  • Specifically, those women who have a family history of this disease and those whose lifestyle's are in a way that makes them more at risk of breast cancer, the examinations and tests should be done on a regular basis in order to cure this diseases at the early stages. (ac.ir)
  • But thanks to the prevalence of medical tourism, patients with breast neoplasms can now undergo cancer treatment in Southeast Asia at 50% to 75% less than its usual cost. (docdoc.com)
  • Mainly taken from risk factors for breast cancer, risk factors can be described in terms of, for example: Relative risk, such as "A woman is more than 100 times more likely to develop breast cancer in her 60s than in her 20s. (wikipedia.org)
  • Fraction of incidences occurring in the group having the property of or being exposed to the risk factor, such as "99% of breast cancer cases are diagnosed in women. (wikipedia.org)
  • Recent research has shown that most of the excess risk of death following breast and colorectal cancer in England compared with Norway and Sweden occurs in older age groups during the first year, and especially in the first month of follow-up. (nature.com)
  • These results suggest that early mortality after a diagnosis of breast or colorectal cancer may be partly due to comorbidity and lifestyle factors, as well as due to more advanced disease. (nature.com)
  • The aim of this study was to examine the characteristics of patients with breast or colorectal cancer who die within 30 days of diagnosis, using health service data collected routinely and, using proxy indicators, to explore the influence of socioeconomic deprivation, co-morbidity, and lifestyle on outcome. (nature.com)
  • Anonymised records relating to patients diagnosed with breast cancer (ICD-10 C50) or colorectal cancer (C18-C20) during the period 2003-2007 were extracted from the Scottish Cancer Registry (SCR). (nature.com)
  • Only the first breast or colorectal cancer arising in an individual was included in the analysis. (nature.com)
  • Unlike breast cancer, colon cancer is thought to be more homogeneous with a single dominant pathway and histological presentation during tumor progression [ 11 ]. (biomedcentral.com)
  • Soft-Tissue Sarcomas, Breast Cancer, and Other NeoplasmsA Familial Syndrome? (annals.org)
  • The increased familial susceptibility to cancer was manifested not only by the large number of members affected but by a seeming excess of multiple primary neoplasms. (annals.org)
  • Should This Woman With Dense Breasts Receive Supplemental Breast Cancer Screening? (annals.org)
  • Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. (bioseek.eu)
  • FRIDAY, Jan. 12, 2018 (HealthDay News) -- Lynparza (olaparib) has been approved by the U.S. Food and Drug Administration to treat spreading breast cancer caused by a BRCA gene mutation. (hon.ch)
  • This class of drugs has been used to treat advanced, BRCA-mutated ovarian cancer and has now shown efficacy in treating certain types of BRCA-mutated breast cancer," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence. (hon.ch)
  • More than 250,000 women in the United States are projected to be diagnosed with breast cancer this year, and more than 40,000 will die from it, according to estimates from the U.S. National Cancer Institute. (hon.ch)
  • About 5 to 10 percent of people with breast cancer have a BRCA mutation, the FDA said. (hon.ch)
  • Lynparza was evaluated to treat breast cancer in clinical studies involving 302 people. (hon.ch)
  • Male breast cancer is a rare entity, with an approximate rate of 1.1 / 100 000 in the US, with an average age of 67 years. (nih.gov)
  • 53 -year-old male diagnosed with right breast cancer, infiltrating ductal adenocarcinoma type, clinical stage IIB, breast cancer on 2 immediate family history, mutations of the BRCA1 gene and positive hormone receptors and Her2/Neu. (nih.gov)
  • Breast cancer in male patient has a worse prognosis than female patients, due to lower amount of tissue in breast exposed to an earlier chest spread and a different biological behavior, also a higher risk of prostate and pancreatic cancer is associated. (nih.gov)
  • Studies of adequate methodological quality are scarce, so that decisions are based on guidelines for breast cancer in women. (nih.gov)
  • Breast cancer accounts for one-third of cancer diagnoses and 15% of cancer deaths in U.S. women. (wiley.com)
  • Over one-half of the 300,000 breast cancer deaths worldwide in 1990 (the latest year with such data) occurred in developed countries, but annual mortality rates ranged from 27/100,000 women in northern Europe to 4/100,000 women in Asia. (wiley.com)
  • FRIDAY, Sept. 29, 2017 (HealthDay News) -- Verzenio (abemaciclib) has been approved by the U.S. Food and Drug Administration to treat women with certain advanced forms of breast cancer, the most common cancer in the United States. (hon.ch)
  • The drug is approved for hormone receptor-positive and HER2-negative forms of advanced or spreading breast cancer that have been treated with a therapy that changes a person's hormones (endocrine therapy). (hon.ch)
  • Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike [similar drugs], it can be given as a standalone treatment to patients who were previously treated with endocrine therapy and chemotherapy," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence. (hon.ch)
  • The drug was evaluated in clinical studies involving almost 700 people whose breast cancer had progressed after treatment with endocrine therapy. (hon.ch)
  • Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy. (nih.gov)
  • Breast cancer in young women has been shown to have an aggressive behavior and worse prognosis. (nih.gov)
  • Abstract Two hundred and thirty-five consecutive patients presenting to a single center with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer treatment were compared with matched patients with de novo AML or MDS. (elsevier.com)
  • Having therapy-related disease is not an independent risk factor in patients with myeloid neoplasms and with a history of breast cancer. (elsevier.com)
  • Additionally, this study will characterize the pharmacokinetics parameters in Chinese postmenopausal women with advanced breast cancer. (clinicaltrials.gov)
  • Estrogen receptor (ER) and / or progesterone receptor (PR) positive breast cancer confirmed by pathology. (clinicaltrials.gov)
  • Once received a non-steroidal aromatase inhibitor (letrozole / anastrozole) treatment, the disease recurrence or progression of breast cancer currently. (clinicaltrials.gov)
  • This multicenter, single-arm observational study will evaluate the clinical benefits of Avastin (bevacizumab) in combination with paclitaxel in first-line treatment in patients with metastatic breast cancer. (clinicaltrials.gov)
  • Patients with metastatic breast cancer who have started Avastin treatment within 6 months prior to study start will also be eligible. (clinicaltrials.gov)
  • Number of participants at each Metastatic breast cancer stage 0, I, II, III or IV, at the point of diagnosis is reported. (clinicaltrials.gov)
  • Breast cancer-a diagnosis that would daunt any woman. (who.int)
  • This very personal and uplifting account of one Egyptian woman's experience with breast cancer offers hope to all. (who.int)
  • The widespread use of triclosan and its detection in human breast milk, urine, and serum have raised concerns regarding its association with various health outcomes, including cancer development [ 4 ]. (mdpi.com)
  • Breast cancer remains a common and frequently fatal disease, the most commonly diagnosed cancer in women and the second leading cause of cancer death in the Eastern Mediterranean Region. (who.int)
  • Although breast cancer is much more common in women, men can get it too. (medlineplus.gov)
  • Breast lumps usually aren't cancer. (medlineplus.gov)
  • However, most men with breast cancer have lumps. (medlineplus.gov)
  • Risk factors for male breast cancer include exposure to radiation, a family history of breast cancer, and having high estrogen levels, which can happen with diseases like cirrhosis or Klinefelter's syndrome . (medlineplus.gov)
  • Treatment for male breast cancer is usually a mastectomy , which is surgery to remove the breast. (medlineplus.gov)
  • Can Breast Cancer in Men Be Found Early? (medlineplus.gov)
  • How Is Breast Cancer in Men Diagnosed? (medlineplus.gov)
  • We report our experience with adverse reactions to isosulfan blue dye during SLN mapping in breast cancer. (nih.gov)
  • We report the largest single-institution review of adverse reactions to injection of isosulfan blue dye during sentinel lymph node mapping in breast cancer. (nih.gov)
  • The author combines a complete, superbly illustrated atlas of imaging findings with a comprehensive text that covers all imaging modalities and addresses all aspects of breast imaging-including breast anatomy, histology, physiology, pathology, breast cancer staging, and preoperative localization of occult lesions. (powells.com)
  • DelveInsight's " Triple Negative Breast Neoplasms - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Triple Negative Breast Neoplasms , historical and forecasted epidemiology as well as the Triple Negative Breast Neoplasms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. (delveinsight.com)
  • The Triple Negative Breast Neoplasms market report provides current treatment practices, emerging drugs, Triple Negative Breast Neoplasms market share of the individual therapies, current and forecasted Triple Negative Breast Neoplasms market Size from 2017 to 2030 segmented by seven major markets. (delveinsight.com)
  • The Report also covers current Triple Negative Breast Neoplasms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. (delveinsight.com)
  • The DelveInsight Triple Negative Breast Neoplasms market report gives a thorough understanding of the Triple Negative Breast Neoplasms by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. (delveinsight.com)
  • It covers the details of conventional and current medical therapies available in the Triple Negative Breast Neoplasms market for the treatment of the condition. (delveinsight.com)
  • It also provides Triple Negative Breast Neoplasms treatment algorithms and guidelines in the United States, Europe, and Japan. (delveinsight.com)
  • The Triple Negative Breast Neoplasms epidemiology division provide insights about historical and current Triple Negative Breast Neoplasms patient pool and forecasted trend for every seven major countries. (delveinsight.com)
  • The disease epidemiology covered in the report provides historical as well as forecasted Triple Negative Breast Neoplasms epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. (delveinsight.com)
  • The epidemiology segment also provides the Triple Negative Breast Neoplasms epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. (delveinsight.com)
  • Drug chapter segment of the Triple Negative Breast Neoplasms report encloses the detailed analysis of Triple Negative Breast Neoplasms marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. (delveinsight.com)
  • It also helps to understand the Triple Negative Breast Neoplasms clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. (delveinsight.com)
  • The report provides the details of the marketed product available for Triple Negative Breast Neoplasms treatment. (delveinsight.com)
  • The report provides the details of the emerging therapies under the late and mid-stage of development for Triple Negative Breast Neoplasms treatment. (delveinsight.com)
  • The Triple Negative Breast Neoplasms market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Triple Negative Breast Neoplasms market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. (delveinsight.com)
  • The preoperative clinical workup of an apparently healthy patient with a breast mass can be cursory and is unlikely to exclude a metastasis from a clinically inapparent (that is, "occult") nonmammary malignant neoplasm (NMMN). (basicmedicalkey.com)
  • Thus, when faced with a mammary neoplasm that has unusual clinical, radiologic, or histologic features, it is important to consider metastasis in the differential diagnosis. (basicmedicalkey.com)
  • In approximately one-third of the cases, the metastasis in the breast is the first presentation of the NMMN. (basicmedicalkey.com)
  • Metastasis from the contralateral breast is a diagnostic consideration when there is bilateral involvement (or history thereof), the histologic appearances of the tumors in the breasts are similar, and there is no evidence of in situ carcinoma in the contralateral breast. (basicmedicalkey.com)
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified ( C25.9 ). (icd10data.com)
  • Metastases from NMMN are rare and account for less than 1% of all mammary malignant neoplasms in clinical series, and up to 5% of autopsies of patients who die as a result of NMMN ( 1 ). (basicmedicalkey.com)
  • Inflammatory Breast Neoplasms research, articles, guidelines & medical evidence database search. (doctorasyou.com)
  • Access the latest scientific research and medical evidence related to Inflammatory Breast Neoplasms treatment, diagnosis and symptoms, quickly and easily with doctorAsyou. (doctorasyou.com)
  • 12 A breast benign neoplasm that forms from cells that release hormones into the blood in response to a signal from the nervous system. (malacards.org)
  • Breast Neuroendocrine Neoplasm, also known as neuroendocrine tumor of the breast , is related to neuroendocrine tumor and peritoneal serous adenocarcinoma . (malacards.org)
  • An important gene associated with Breast Neuroendocrine Neoplasm is SYP (Synaptophysin). (malacards.org)
  • This system uses sound waves to create 3D images of the breast, showing a better picture of the tumor. (knowcancer.com)
  • Primary desmoid tumor (extraabdominal fibromatosis) of the breast. (radiopaedia.org)
  • Well-differentiated neuroendocrine tumor of the breast with extensive lymphatic and vascular infiltration. (malacards.org)
  • Well-differentiated neuroendocrine tumor of the breast with recurrence due to needle tract seeding. (malacards.org)
  • Primary neuroendocrine tumor of the breast. (malacards.org)
  • Expression patterns for terminal differentiation markers were used to characterize tumor types and to study tumor progression in transgenic mouse models of mammary neoplasia (mice overexpressing Neu ( Erbb2 ), Hras , Myc , Notch4 , SV40-TAg , Tgfa , and Wnt1 ), in spontaneous mammary carcinomas, and in mammary neoplasms associated with infection by the mouse mammary tumor virus (MMTV). (biomedcentral.com)
  • and third, 'carcinomas with epithelial to mesenchymal transition (EMT)' are a characteristic feature of tumor progression in Hras- , Myc- , and SV40-TAg- induced mammary neoplasms and PL/J and SJL/J mouse strains, and display de novo expression of myoepithelial and mesenchymal cell markers. (biomedcentral.com)
  • However, because of overlapping of cytologic features, surgical excision should be warranted in all cases of papillary lesions of the breast to further characterize the tumor. (jpatholtm.org)
  • A urogenital neoplasm is a tumor of the urogenital system. (icd.codes)
  • Tumor heterogeneity is defined as the simultaneous presence of multiple clonal subpopulations of tumor cells within a single neoplasm [ 1 ]. (biomedcentral.com)
  • 40 years regarding the achievement of a pCR (defined as no invasive residual tumor in the breast or lymph nodes). (nih.gov)
  • Postmenopausal women with histologically confirmed, measurable locally advanced disease or metastatic breast. (knowcancer.com)
  • A series of metastatic breast carcinoma (MBC) mimicking visceral well-differentiated neuroendocrine neoplasms has not previously been reported. (elsevier.com)
  • The generally accepted definition of MPC was introduced by Worren and Gates, who stated that each neoplasm must represent a distinct malignancy, and that a metastatic origin must be excluded [ 6 ]. (biomedcentral.com)
  • Hematopoietic and lymphoid neoplasms involving the breast are sometimes listed under the rubric of breast "metastases," but they are best regarded as either primary breast neoplasms or as a manifestation of a systemic condition, depending upon the extent of organ involvement. (basicmedicalkey.com)
  • If hematopoietic and lymphoid neoplasms are excluded, the most common NMMNs that secondarily involve the breast include carcinomas of the lung, ovary, stomach, kidney, and cutaneous melanoma. (basicmedicalkey.com)
  • Although many of the epithelial lesions/changes listed below are neoplastic, they are best thought of as neoplasms at increased risk and along a continuum with normal breast at one end and invasive carcinoma at the other. (radiopaedia.org)
  • Over the past 20 years, immunohistochemistry has added a molecular dimension to the categorization of mammary neoplasms: altered expression of oncogenes, oncosuppressor genes, hormone receptors, and cytoskeletal proteins have been identified as useful indicators of disease outcome. (biomedcentral.com)
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. (icd10data.com)
  • Noncytokeratin expressing primary melanoma of the breast is neurogenic in origin and cytokeratin-negative. (basicmedicalkey.com)
  • Nonetheless, primary melanocytic lesions of the breast are exceedingly less common than metastatic melanocytic neoplasms. (basicmedicalkey.com)
  • Among the metastatic carcinomas in the breast that are most likely to be mistaken for a breast primary are those arising in the lung, ovary, mullerian system, and bowel. (basicmedicalkey.com)
  • To the best of our knowledge, this is the first reported case in literature of this combination of primary neoplasms. (biomedcentral.com)
  • Male Breast Neoplasms anonymous support group with information on diagnosis, treatment, symptoms, along with personal stories and experiences with Male Breast Neoplasms. (experienceproject.com)
  • Breast Myoepithelial Neoplasm, also known as malignant breast myoepithelioma , is related to breast adenomyoepithelioma and breast myoepitheliosis , and has symptoms including pain An important gene associated with Breast Myoepithelial Neoplasm is HSD11B2 (Hydroxysteroid 11-Beta Dehydrogenase 2), and among its related pathways/superpathways are Keratinization and Cytoskeleton remodeling Neurofilaments . (malacards.org)
  • paciente masculino de 53 años de edad, con diagnóstico de cáncer de mama derecha, tipo adenocarcinoma canalicular infiltrante, estadio clínico IIB, con antecedentes de cáncer de mama en 2 familiares directos, mutaciones del gen BRCA1 y positivo tanto a receptores hormonales como para el gen Her2/Neu. (nih.gov)
  • Breast Neoplasms complications. (illinois.edu)
  • The concept Breast Neoplasms -- complications -- popular works represents the subject, aboutness, idea or notion of resources found in College of Physicians of Philadelphia . (collegeofphysicians.org)
  • This may be because the breasts are exposed to estrogen for a longer period. (knowcancer.com)
  • Fortunately, the majority of breast lumps are non-malignant cysts or fibrous tissue. (giantmicrobes.com)
  • Breasts are considered "dense" when there is a high ratio of tissue to fat. (knowcancer.com)
  • Excised fresh breast tissue for evaluation and/or treatment of a variety of breast lesions were sampled by FNA technique and placed into PreservCyt. (nih.gov)
  • In conclusion, FNA of breast tissue placed in PreservCyt is a potentially acceptable method of sample handling for evaluation by the SELDI-TOF methodology for establishment of reproducible protein patterns. (nih.gov)
  • Radiologic techniques such as MRI (magnetic resonance imaging) and FDG-PET/CT (fluorodeoxyglucose-positron emission tomography-computed tomography) have also detected metastases in the breast from carcinoma of the thyroid ( 7 ), ovary ( 8 ), and soft tissue liposarcoma ( 9 ). (basicmedicalkey.com)
  • After 109,560 person-years of follow-up, the overall rate of marrow neoplasms in the entire cohort was 0.46 per 1,000 person-years, with rates per 1,000 person-years of 0.16 in those receiving surgery alone, 0.43 in those receiving adjuvant radiation alone, 0.46 in those receiving adjuvant chemotherapy alone, and 0.54 in those receiving both adjuvant treatments. (ascopost.com)
  • C79.81 is a billable code used to specify a medical diagnosis of secondary malignant neoplasm of breast. (icdlist.com)